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Sammendrag
Kreft og kardiovaskulære sykdommer er ledende dødsårsaker i industriland og i mange 
utviklingsland. De eksisterende kliniske og patologiske verktøy for disse sykdommene 
er ikke tilstrekkelige for å gi presis prediksjon av respons eller optimal individualisert 
behandling. Det er derfor et stort behov for å identifisere og implementere nye 
biomarkører for å oppnå bedre prediktiv, forebyggende og målrettet medisin.
Endring i cellenes stoffskifte er en viktig faktor i utviklingen av kreft og kardiovaskulær 
sykdom og derfor et viktig område innen biomedisinsk forskning. Studiet av små 
molekylære metabolitter i kroppsvæsker og vevsprøver (metabolomics), kan ved hjelp 
av magnetisk resonans spektroskopi (MRS) og multivariate dataanalyser, gi ny innsikt 
innenfor dette feltet. Identifikasjon av nye metabolske biomarkører for prediksjon, 
diagnose og behandlingsrespons av kardiovaskulær sykdom og kreft, har potensiale til å 
øke total overlevelse og pasientens livskvalitet, i tillegg til å spare samfunnet for store 
utgifter. 
Økt forekomst av livsstilssykdommer er en trussel mot folkehelsen, og det er behov for 
mer effektive forebyggings- og behandlingsstrategier. Flere studier har vist at 
forekomsten av metabolsk syndrom og kardiovaskulær sykdom er relatert til 
kondisjonsnivå. Lav maksimal aerob kapasitet er foreslått som en prediktiv faktor for 
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kardiovaskulær død. De eksakte molekylære mekanismene bak dette er uklare. Studier 
basert på metabolomics har resultert i unike funn som kan gi informasjon om de 
underliggende mekanismene til koronar hjertesykdom, kreft, kosthold og livsstil. Innen 
kreftforskning har metabolomics også et potensiale som et ekstra verktøy i 
diagnostisering og risikovurdering. Videre vil det være et relevant verktøy for å finne 
optimal individualisert behandling, med andre ord kun behandle pasienter som med 
størst sannsynlighet har effekt av en spesifikk behandling og dermed kan unngå 
unødvendig behandling.
Hovedmålet med forskningen presentert i denne avhandlingen var å evaluere bruken av 
metabolomics basert på bruk av høyoppløselig MRS og multivariat dataanalyse for å 
identifisere og karakterisere mulige biomarkører for ulike helsetilstander. Avhandlingen 
består av tre artikler hvor anvendelsen av MR metabolomics til å identifisere 
biomarkører for kondisjon, astrocytom grad og endringer i bukhinne-/pleuravæske fra 
kreftpasienter etter kjemoterapi ble evaluert.  Studiene ble utført i prøvematerialer fra et 
bredt spekter av mennesker, og spenner fra friske frivillige til pasienter med avansert
kreftsykdom.
I den første studien ble kondisjonsavhengige forskjeller i serumnivåer av fritt kolin og 
fosfatidylkolin i en gruppe friske frivillige observert. Resultatene viser at 
kolinmetabolitter er potensielle tidlige markører for kardiovaskulær sykdomsrisiko og 
bør studeres nærmere. I neste studie ble muligheten for å differensiere diffuse 
hjernesvulster av Grad II og IV astrocytom basert på metabolske profil vist. I det siste 
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arbeidet ble metabolske markører for kjemoterapirelaterte endringer i bukhinnevæske 
fra pasienter med eggstokkreft identifisert.
Denne avhandlingen har vist nytten av MR metabolomics og multivariat dataanalyse i 
utredningsfasen av biomarkører. Videre har nytten av MR baserte metabolomics 
teknikker for å finne molekylære signaturer av kreft og kondisjon blitt studert. Dette kan 
bidra ytterligere til den vitenskapelige forståelsen av underliggende biologi av svulster 
og kondisjon. 
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Summary
Cancer and cardiovascular disease are the leading cause of mortality in the developed 
countries and in many developing countries. The existing clinical and pathological tools 
for both these diseases are insufficient for accurate response prediction, or for an 
individualized treatment. There is a compelling need for identification and development 
of new biological markers to achieve a new era of predictive, preventive and targeted 
medicine.
Altered cellular metabolism is an important factor in the pathogenesis of cancer and 
cardiovascular disease and has become a major area of biomedical research. 
Metabolomics, the study of small molecular metabolites present in biofluids and tissue 
samples using magnetic resonance spectroscopy may hold the power to bring new 
insights on this subject. Identification of metabolic biomarkers for cardiac disease and 
cancer risk prediction, diagnosis and treatment response could have the power to 
increase overall survival and the patient quality of life, in addition to saving huge 
expenses for the society.
Increased prevalence of lifestyle-related diseases is an impending threat to public health, 
and calls for effective prevention and treatment strategies. Several studies have 
indicated that the occurrence of metabolic syndrome and cardiovascular disease are 
related to the exercise capacity. Low maximal aerobic capacity is suggested as a 
predictive factor for cardiovascular deaths. However, the exact molecular mechanisms 
behind this are unclear and are difficult to explore. Metabolomics based approach may 
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provide potential information in this direction and has resulted in unique findings in 
relation to coronary heart disease, cancer, diet, and lifestyle. The potential benefits of 
metabolomics within cancer research would be to serve as an additional tool in 
diagnosis and risk evaluation. In addition, targeting of specific patients who are more 
likely to benefit from a specific treatment than those who may not benefit from it or 
may be harmed is highly relevant. 
The main objective of the research presented in this thesis was to evaluate the use of 
high resolution magnetic resonances (MR) spectroscopy together with multivariate 
analysis based metabolomics for identifying and characterizing potential biomarkers of 
health-disease continuum. This thesis consists of three papers in which the applicability 
of MR metabolomics in identifying biomarkers of aerobic fitness, astrocytoma grading 
and chemotherapy dependent changes in malignant serous effusion was investigated. 
Metabolomic studies were performed on a broad range of subjects ranging from healthy 
volunteers to patients with advanced stage of malignancies.
In the first study, aerobic fitness dependent differences in serum levels of free choline 
and phosphatidylcholines in a group of healthy volunteers were observed. These choline 
metabolites are potential early markers of CVD risk and should be studied further. In 
the next study, the possibility of differentiating diffuse World Health Organization 
Grade II and IV astrocytoma based on their metabolic profiles were shown.  In the third 
paper, metabolic markers of chemotherapy related changes in ovarian serous carcinoma 
effusions were identified. 
x
The usefulness of MR metabolomics together with multivariate data analysis in the 
exploratory phase of biomarker discovery has been illustrated in this thesis. 
Furthermore, the usefulness of MR based metabolomic techniques in capturing 
molecular signatures of cancers and aerobic fitness has been explored and may 
contribute further to the scientific understanding of underlying tumor biology and 
aerobic fitness.
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Introduction
1 Introduction
1.1 Motivation
Cancer and coronary heart disease (CHD) are the leading causes of death in the majority 
of developed and many developing countries in the world.1,2 Despite the impressive 
progress in medical, scientific and technological achievements over the past decades, 
the prevalence of these diseases has reached alarming proportions. Existing diagnostic 
tools in the clinics are often insufficient for early diagnosis, risk stratification and in 
treatment response prediction. Hence, there is an urgent need to develop tools for early 
risk prediction, to actuate prevention strategies and to optimize the therapeutic regime to 
achieve a successful clinical outcome.
Biological mechanisms underlying cancers and CHD are complex and not fully
understood. There is an intricate interplay of genetic, environmental, and lifestyle 
factors involved in the pathogenesis of these diseases. Unraveling the complex 
association between disease phenotype and the individual’s genetic makeup is a 
challenging task. Recently, the use of molecular tools are gaining much attention in
detecting and studying DNA, RNA, proteins and metabolites to understand the 
biological basis of cancers and heart diseases. It is now possible to perform 
comprehensive and non-targeted analysis of gene products (i.e. RNA, proteins, and 
metabolites) present in a specific biological sample. These high throughput analytical 
techniques generate enormous amount of data which needs sophisticated computational 
methods for interpretation. A new field of research called systems biology has emerged 
1
Introduction
which use a global top-down approach to elucidate the complex behavior which are 
difficult to explain by targeted experiments.3
Systems analysis of -omic (genomic, transcriptomic, proteomic or metabolomic) data 
helps to identify the biological processes and pathways which are most affected in the 
system being studied and help to highlight the key genes, proteins and metabolites as
potential biological indicators and drug targets. These biological indicators are also 
known as biomarkers, and they help to identify differences in disease populations and 
mark response to therapeutic strategies. The complex and interconnected nature of 
biological processes which underlines health and disease responses offers unique 
opportunities for using systems approaches to identify novel biomarkers. A systems 
perspective on disease involves the integration of several elements, from genome 
through phenotype as depicted in Fig. 1.1
Within systems biology, metabolomics has become a key platform, allowing the 
comprehensive and high throughput study of small molecular weight substances in 
cells, tissues and/or whole organisms. Metabolites represent the downstream products of 
gene expression and are closer to the phenome than the proteome or transcriptome.
Even subtle changes in the genes or proteins can give rise to as much as 10,000-fold 
change in the concentration of certain metabolites.4 The future of metabolomics lies on 
its ability to capture even smaller perturbations in the metabolome which occurs prior to 
the gross phenotypic manifestation of the disease.
2
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Figure 1.1: Different levels of “omics” cascade. Integrated analysis of quantitative 
measurements at different levels of the cascade is used in the systems perspective of complex 
diseases. Metabolites lies close to the phenome and may better represent the dynamic changes 
in the phenotypes.
Biological mapping and identification of biomarkers using metabolomics is a rapid and 
objective technology with high clinical relevance within risk screening, patient 
stratification, and preventive medicine and in treatment monitoring. Further, application 
of metabolomic techniques can contribute to achieve a biological understanding of 
complex diseases and can complement the knowledge gained from other molecular 
techniques. Considering the complexity of most common diseases, a panel of 
biomarkers which portrays the major aspects of pathophysiology may provide 
additional information to the clinicians. Clinical decision making based on a panel of 
biomarkers may address the future goal of personalized medicine by identifying the 
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individuals who will better benefit from a specific therapy. This thesis is aiming to 
identify and develop potential biomarkers of healthy and diseased state by applying
metabolomics.
1.1.1 Aerobic fitness
Aerobic fitness refers to endurance or the ability to exert for an extended period of 
time.5 During aerobic exercise, oxygen is consumed from the atmosphere and is 
transferred to the muscles via the circulatory system. An individual’s aerobic fitness is 
dependent on age and sex, and can be improved by exercise. The indicator of aerobic 
fitness level is known as maximal oxygen uptake (VO2max). VO2max is determined by the 
measurement of oxygen uptake during the performance of maximal work, typically 
while running on a treadmill or while cycling (Figure 1.2). VO2max is often expressed as
the maximum volume of oxygen consumed per minute. It may also be expressed as the 
absolute volume of oxygen consumed in liters per minute to indicate total work 
capacity, or volume of oxygen consumed per minute per kilogram body weight.6
As with other physiological functions, there are large individual variations in VO2max of 
subjects of the same age and gender. Some people show high VO2max without regular 
exercise owing to genetics and other factors, while some other people who exercise 
regularly do not show high VO2max. Genetics plays a major role in a person’s VO2max
and heredity can account for up to 25-50% of the variance seen between individuals.7
4
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Figure 1.2: Maximal oxygen uptake. The point at which the oxygen consumption saturates is 
the VO2 max or the maximum oxygen uptake of an individuals. Adapted from Kent8
Several studies report that aerobic fitness level, measured by the VO2max, is the single 
best predictor of future CVD mortality in healthy people.9-13 Aerobic power appears to 
have more of an influence on CVD risk factors than physical activity level.14 Based on 
this, more knowledge of the differences between healthy individuals with a large 
difference in VO2max-level will be of great interest to identify novel biomarkers of low 
aerobic fitness that may also have a potential as an early biomarker of CVD risk.13,15-19
Identifying early markers of aerobic fitness may be helpful in actuating preventive
strategies in individuals before developing the symptoms of CVD. Furthermore, such 
markers may be of help in contributing towards the deeper understanding of the 
complex molecular mechanisms behind fitness and cardiovascular diseases.
1.1.2 Cancer metabolism 
Cancer is a disease characterized by uncontrolled proliferation of cells in which the cells 
acquire genetic changes that allows them to evade the normal growth regulatory signals. 
5
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The key biological changes occurring in the development of cancer, the hallmarks of 
cancer, are sustained proliferative signals, evasion of growth suppressors, resistance to 
cell death, attaining replicative immortality, induction of angiogenesis and activation of 
invasion and metastasis.20 Reprogramming of cellular metabolism and evasion of 
immune mediated destruction has recently been added as two emerging hallmarks. 
Metabolic changes occurring in connection with cancer has been noticed almost a 
century ago by Otto Warburg in his description of a switch in glucose metabolism from 
oxidative phosphorylation to glycolysis — the Warburg effect.21 In order to support the 
high rate of cellular proliferation, cancer cells show a shift in its metabolism towards 
biosynthesis. 
Intrinsic genetic mutations and external responses to the tumor microenvironment in 
turn control the metabolic phenotypes of tumor cells. Alteration in the cellular growth 
signaling pathways in cancer cells changes the cellular metabolism to match the need of 
cell division. Changes occur in the cellular metabolism of cancer cells to provide a 
continuous and rapid energy supply (ATP synthesis).22 Beyond the Warburg effect,
other changes can occur in the glycolytic pathway (e.g. up regulated M2 isoform of 
pyruvate kinase) to channel substrates through alternative pathways like the pentose 
phosphate pathway (PPP) and other pathways so that large quantities of reduced 
nicotinamide adenine dinucleotide phosphate (NADPH) and other macromolecules are 
produced.22,23
Phospholipids play an important role in proliferating cells as they form an important 
component of the cell membrane. In eukaryotic cell membrane, phosphatidylcholine 
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(PtdCho) is the most abundant phospholipid.24 Phosphocholine (PCho, a precursor and a 
breakdown product of PtdCho) together with other phospholipids such as 
phosphatidylethanolamine (PtdEtn) and neutral lipids forms the characteristic bilayer 
structure of cellular membrane.25 Changes in the levels of choline containing 
metabolites are observed in most cancers and have complex links to malignant 
transformation and oncogenic signaling.25 This is further complicated by factors like 
hypoxia and acidic pH in tumor microenvironment which will also contribute to 
alteration in choline metabolites.25,26
Cancer cells are usually under higher oxidative stress compared with normal cells. The
production of two of the most abundant antioxidants, reduced NADPH and glutathione 
(GSH), has been shown to be modulated in cancers. Shunting of glycolysis through PPP 
results in NADPH production which can act as a crucial anti-oxidant and can fuel 
macromolecule synthesis.27 Hence, the metabolic alterations present in cancer cells 
promote not only ATP resources, but also macromolecular biosynthesis and redox 
control (Figure 1.3).
7
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Figure 1.3: The metabolic reprogramming in tumor cells. Small arrows pointing up or down 
indicate cancer associated upregulation or downregulation of enzymes. Changes indicated in red 
can be caused by the activation of HIF-1. CA9 and CA12, carbonic anhydrases 9 and 12; CPT, 
carnitine palmitoyltransferase; GLUT, glucose transporter; GSH, glutathione; HIF, hypoxia-
inducible factor; IDO, indoleamine 2,3-dioxygenase; HK, hexokinase; OXPHOS, oxidative 
phosphorylation; LAT1, L-type amino acid transporter 1; LDHA, lactate dehydrogenase 
isoform A; MCT, monocarboxylate transporter; PDH, pyruvate dehydrogenase; PDK, pyruvate 
dehydrogenase kinase; PFK, phosphofructokinase; PI3K, phosphatidylinositol 3-kinase; PGM, 
phosphoglycerate mutase; PKM2, pyruvate kinase isoform M2; PPP, pentose phosphate 
pathway; SCO2, synthesis of cytochrome c oxidase 2; TLK, transketolase; VDAC, voltage-
dependent anion channel. Reprinted with permission from Kroemer et al.28
Genetic mutations in the isocitrate dehydrogenase gene (IDH1/2) with the production of 
an 'oncometabolite' 2-hydroxyglutarate (2HG) have been found in gliomas and 
leukemias.29 Specifically this mutation is seen in more than 70% of the secondary 
gliomas. This finding strengthens the links between mutations in metabolic genes and 
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common cancers and opens up potential opportunities in exploring metabolic targets in 
brain cancers and leukemias for diagnosis and prognostication.30
1.1.3 Astrocytomas
Astrocytomas are one of the most common primary brain tumors in humans and are 
subdivided into histological grade II - IV according to the WHO classification (Table 
1.1). They arise from the star-shaped cells (astrocytes) that form the supportive tissue of 
the brain. Apart from astrocytes, other supporting cells in the central nervous system 
include oligodendrocytes and ependymal cells. Tumors arising from these supporting 
cells, also known as glial cells are collectively known as gliomas. Noninfiltrating 
astrocytomas usually grow more slowly than the infiltrating forms. Infiltrating, or 
diffuse astrocytomas are more common than noninfiltrating astrocytomas.31 They are 
generally more common in men and are most common in the cerebral hemispheres of 
adult patients. Due to the infiltrative growth into adjacent brain tissue a complete 
surgical removal is not possible. Diffuse astrocytomas tend to recur and lower grades 
frequently undergo malignant transformation despite advances in radiotherapy and 
chemotherapy.32 As there are differences in the management of high and low grade 
astrocytomas, it is essential to identify molecular and metabolic factors that may stratify 
these patients with regards to optimal treatment and prognostication.
9
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Table 1.1: WHO Classification (Adapted from Louis et al.33 )
Grade Prognosis Examples
I Excellent prognosis Juvenile pilocytic astrocytomaPleiomorhic xanthroastrocytoma
II Variable Prognosis Astrocytoma
III Poor prognosis Anaplastic astrocytoma
IV Aggressive tumor Glioblastoma multiforme
1.1.4 Malignant serous effusions
Serous cavities in the human body are the mesothelial lined potential spaces 
surrounding lung, heart and abdomen. Normally these cavities are obliterated and 
contain a very small amount of fluid, which is an ultrafiltrate of plasma. When the 
production and resorption of this ultrafiltrate are unbalanced, fluid may accumulate, 
resulting in an effusion. It is believed that the mechanisms underlying malignant 
effusion accumulation include lymphatic obstruction by metastatic cells impeding the 
outflow of peritoneal fluid, increased vascular permeability and new blood vessel 
formation, increased production by lining cells, changes in the peritoneal stroma and 
fibrin accumulation.34,35 A major portion of the increase in vascular permeability which 
contributes to effusion formation is caused by malignancy-induced angiogenesis, 
resulting in accumulation of protein-rich fluid (a filtrate of whole blood) in the 
peritoneal cavity. The accumulation of malignant effusions is a common event in 
clinical practice. The diagnosis of malignant effusion indicates disease progression and 
is associated with a worse prognosis. Effusions containing tumor cells may accumulate 
10
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within the serosal cavities, i.e. the peritoneal, pleural and pericardial cavity in 
practically every cancer type. In adults, the most common organs of origin are the 
breast, lung and ovary, with gastrointestinal cancers as an additional relatively common 
origin, especially in Asian countries.34 In addition to metastases, the serosal cavities are 
the site of origin of several cancers, including malignant mesothelioma and primary 
peritoneal carcinoma, although these are by far outnumbered by metastatic cancer. The 
finding of cancer cells in effusions is generally a marker of advanced-stage disease and 
is associated with poor survival in the majority of cases.34 Often, the patients with 
malignant effusions are in a critically ill situation, and it is difficult to obtain a tissue 
sample or metastatic nodule for biopsy. In these patients, the analysis of the malignant 
fluid may be the only feasible option. Malignant effusions in serosal cavities represent 
an important source for potential metabolic markers. It may aid in understanding more 
about the metabolic basis behind malignant effusions, to identify novel biomarkers for 
diagnosis and treatment and to discover potential targets for therapy.
1.2 Metabolomics
Metabolomics provides a ‘top down’ integrated view of complex biochemical events
occurring in complex organisms by measuring the global, dynamic metabolic responses 
with a wide array of analytical techniques. Magnetic resonance spectroscopy (MRS) and 
mass spectrometry (MS) are the most commonly used analytical methods for 
metabolomic studies.36 These techniques also help in metabolite identification by
providing information on the metabolite structure.37 Owing to the diversity in 
metabolites with different physical and chemical composition, it is practically 
impossible to explore the entire metabolome using a single analytical technique. Even 
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though there is an intimate connection between genes, proteins and metabolites in a 
biological system, gene and protein expressions often may not directly correlate to the 
metabolite concentrations. This emphasise clearly the need for an additional 
measurement at the metabolite level and the role of metabolomics in studying 
gene/environment interactions (Fig 1.4).38
Figure 1.4: Metabolomics to study gene/environment interactions. Metabolism can be affected 
in two different ways in an extreme scenario. In the first case, a small mutation in the genome 
can cause minor changes in the transcriptome but a bigger change in the metabolome. Secondly, 
to maintain the homeostasis of the biological system in response to stressful stimuli, a large 
change in the transcriptome and proteome can occur with minimal change in the metabolome, 
hence maintaining the metabolic homeostasis.  The figure is reprinted with permission from 
Manuel Mayr. 38
Although classic genetics aims to relate the DNA sequences directly to the phenotype, 
“-omic” technologies allows to move the focus from a specific gene to the actual effect 
of the gene. Since it is impossible to correlate the gene or protein profiles directly to the 
12
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metabolic composition, the importance of measuring small molecular weight 
metabolites are gaining wider attentions. By “metabolomic profiling”, it is now possible 
to perform quantitative and qualitative measurement of a subset of metabolites in 
biological samples such as body fluids and tissues. Similar to other “-omic” studies, 
metabolomics aims for objective and unbiased measurements of metabolite dynamics.39
Metabolomic studies offer certain advantages. Being downstream in the traditional 
biological information cascade from genes, transcripts and proteins, metabolic 
perturbations will be more close to the phenotype. The metabolome is highly dynamic 
and changes can occur in short intervals of time (within seconds), and can thus be a 
rapid indicator of biological changes. Hence metabolic perturbations may have the 
potential for capturing early changes in clinical systems far ahead of the appearance of 
disease symptoms and more invasive measures are required.16
A typical metabolomic study follows a common workflow.16,39,40 It starts with a 
biological question and experiment followed by sample collection. After sample 
preparation, appropriate analytical experiment(s) are performed to acquire data.  The 
high density metabolic data is then subjected to pre-processing and analysis followed by 
biological interpretation (Fig. 1.5). The analytical techniques MRS and MS are 
commonly used for metabolomics studies. Both techniques have their own advantages 
and disadvantageous. MS is more sensitive than MRS while MRS is more reproducible, 
needs minimal sample preparation and can be performed in a non-destructive manner.
Furthermore, advances in high-field clinical scanners and newer methods for in vivo
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MRS offers potential for future clinical translation of the ex vivo MRS markers to aid in
vivo diagnostics. 
Figure 1.5: Metabolomics Work Flow. Adapted from Mamas M. et al39
1.2.1 MR spectroscopy
MR Spectroscopy (MRS) is an analytical technique which can detect and quantify a
wide range of biochemical metabolites. All nuclei with non-zero spin have an intrinsic 
magnetic moment and may be studied by MRS. Spin ½ nuclei that are commonly 
studied include 1H (the most popular nucleus for NMR studies), 13C, 19F and 31P. In 
contrast, the abundant isotopes of carbon and oxygen, 12C and 16O, have an even 
number of both protons and neutrons which form pairs to cancel out the individual spins
and hence cannot be studied by MRS. The high natural abundance of protons (1H) in 
organic compounds and biological samples has made it a common nuclei for magnetic 
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resonance spectroscopy. Phosphorus MRS (31P) is of particular interest for studies on 
phospholipid analysis and energy metabolism.41
Figure 1.6: Basic principles of magnetic resonance. The figure illustrates the different spin 
states, energy differences and the field (B0) frequency relationships. Figure adapted from  Shung 
et al42
In the absence of an external or applied magnetic field (B0), the nuclear spins orient 
randomly. However, when there is an applied magnetic field, the nuclei orient 
themselves with or against the larger applied field. The spin state which is parallel to the 
applied field has lower energy than the spin state which is antiparallel to the applied 
field. The energy difference ¨E between the spin states is proportional to the strength of 
B0 (Figure 1.6). Spins in the lower energy states can be transferred to a higher energy 
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state by applying an external radio frequency (RF) pulse.  Following an RF pulse, spins 
return back to their low energy state, emitting the energy back as radio waves. This 
emitted energy can be detected and forms the basis of the MR signal.
A plot of intensity of MR signal versus the magnetic field frequency is known as the
MR spectrum. When the spins returns back to equilibrium, they go through relaxation 
processes characterized by two time constants called longitudinal (T1) and transverse 
(T2) relaxation. T1 relaxation depends on the net transfer of the energy to the 
environment. Larger molecules like proteins and lipids have a relatively short T1 while 
smaller molecules have a longer T1. The decay of transverse magnetisation (T2) 
depends on the dephasing of individual magnetic moments. Factors like molecular 
motion, viscosity, temperature, free water content, presence of paramagnetic atoms and 
field inhomogeneity can affect the T2. In MR experiments, the T1 and T2 values of 
molecules are important in setting up the correct acquisition protocols.  For obtaining 
accurate relative signal intensities from a sample, a recycle delay of at least five times
the longest T1 has to be used, so that all nuclei can return back from their excited state 
to equilibrium before the subsequent excitation. Similarly large molecules have a short 
T2, which can be exploited to filter out the signals from macromolecules like lipids.
The molecular environment around a nucleus is slightly (typically by a few parts per 
million) modified because of the shielding effect of the electron cloud resulting in small 
changes in the effective magnetic field experienced by the nucleus. This results in small 
changes in the resonance frequency of the given nucleus. Being very small, this shift in 
resonance frequency is expressed in relation to a standard reference frequency and is 
known as the chemical shift.
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Higher magnetic field strength offers well resolved and detailed spectra of small 
metabolites. For example, overlapping resonances from glycerophosphocholine (GPC), 
phosphocholine (PCho), and free choline in vivo, can be studied separately at higher 
field strengths with ex vivo high-resolution MRS. The greater spectral resolution with 
increasing magnetic field strength also enhances the quantification precision.
1.2.2 MRS of biofluids
Metabolic profiling of biofluids can provide an extensive view of changes in 
endogenous metabolites in monitoring cellular responses to normal physiology or 
perturbations such as diseases and drug treatments.43-50 Clinical biomarkers of disease 
conditions are best found in the biofluids which is bathing the most affected organ. For 
example markers of lung diseases may be present in saliva or breath-condensate, 
cerebro spinal fluid for neuronal diseases, urine or blood for kidney diseases, and blood 
for cardiac diseases. Among the biofluids, blood and urine is more widely used for 
clinical metabolomic studies.51-56 Analysis of metabolites in biofluids as a diagnostic 
tool has several advantages such as non-invasive or minimally-invasive sample 
collection and the possibility of multiple sample collection over a time course thus 
making it an ideal choice for clinical studies.57
1.2.3 HR-MAS MRS 
The line width of an MR signal depends strongly on the microscopic environment of the 
nucleus under study. MR spectra from solid or semi-solid tissue samples present much 
broader signals compared to liquid samples due to their large dipolar interactions and 
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chemical shift anisotropy. In liquid samples the rapid isotropic motion of the molecules 
averages the anisotropic interactions, resulting in an isotropic chemical shift frequency 
and a disappearance of the line broadening due to dipolar couplings. In solids, the lack 
of mobility leads to anisotropic broadening and spectra with overlapping signals.58
Figure 1.7: Magic-angle spinning: The sample (blue) is rotating with high frequency inside the 
main magnetic field (B07KHD[LVRIURWDWLRQLVWLOWHGE\WKHPDJLFDQJOHșm with respect to the 
direction of B0. Image credits to Wikimedia Commons.
When the sample is spun at an angle (șm) to the magnetic field (Figure 1.7), the dipolar 
interactions between the nuclei are dependent on the angle and the spin rate. At an angle 
of 54.7 degree also known as ‘magic angle’, some of the dipolar interactions are 
annulled and hence results in improved spectral resolution.58 This technique has been 
successfully used to study the metabolic profiles of intact tumor samples from breast, 
brain, kidney, prostate and lung tumors.59-64 The technique is non-destructive and 
requires only minimal sample preparations. The sample remains intact after the MR 
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experiment and can be used for further analysis like histopathology, proteomics and 
gene expression studies.
1.2.4 MRS data acquisition 
Metabolic data acquisition is typically performed on biofluids or tissue samples 
(biopsies). Typical proton spectra of malignant effusions associated with carcinoma of 
breast, ovary and mesothelioma obtained from a high resolution spectrometer (Fig. 1.8)
are comprised of sharp signals (narrow line width) from low molecular metabolites such 
as sugars, amino acids and small metabolites as well as broad signals from different 
groups of lipids and macromolecules. Most of the biological samples contain a high 
proportion of water protons and the huge size of the water peak can strongly limit the
dynamic range of the metabolite detection and loss of signal from low concentration 
substances. Hence, suppression of water signal by specialised pulse sequences that use 
water presaturation or excitation sculpting is commonly used to improve the signal-to-
noise ratio for endogenous metabolites.65 Based on the differences in spin properties of 
macromolecules and small metabolites, there are several spectral filtering techniques 
which can selectively enhance or suppress specific groups of metabolites. 
Macromolecules tend to have shorter T2 relaxation times and smaller diffusion 
coefficients than those of smaller molecules due to their longer rotational correlation 
times and limited translational motion. Hence it is possible to filter the MR spectra 
based on these properties. Smaller molecules such as endogenous metabolites present in 
biofluids can be observed selectively by applying spin-echo loops (Carr–Purcell–
Meiboom–Gill (CPMG)), based on their longer relaxation times, prior to NMR data 
acquisition. This is known as T2-edited spectroscopy.66
19
Introduction
Figure 1.8: Proton magnetic resonance spectra from malignant effusions: Assignments of 
various metabolites visible in the MR spectra are shown.  The region between 6.9 ppm-7.9ppm 
is scaled up to show the assignments.  The red spectrum is from breast carcinoma effusion, the 
green from mesothelioma and the blue from ovarian carcinoma. Reproduced with permission 
from Vettukattil et al.67
1.3 Data analysis
Metabolomic experiments generate large amounts of data which needs sophisticated and 
powerful computational tools for proper analysis and interpretation. Multivariate data 
analysis techniques are able to tackle the colinearities in the MR spectral variables and 
are commonly used in metabolomic studies. Pattern recognition tools are used to 
analyse the large multivariate datasets. Both unsupervised and supervised techniques 
can be used to derive metabolic profiles.68
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1.3.1 Preprocessing of MR spectra
Prior to multivariate analysis, several preprocessing techniques are applied on the MR 
spectra to improve the quality of the spectral data for multivariate analysis. Optimal 
preprocessing techniques are critical in determining the outcome of data analysis.69
Commonly employed preprocessing routines in MR metabolomic data are baseline 
correction, scaling, normalisation and peak alignment.
Baseline correction is used to remove the baseline distortions in MR spectra. Baseline 
distortion can offset the intensity values and result in inaccuracy in peak assignment and 
quantification. Scaling and normalisation are used to make the data from all samples 
directly comparable to each other. Special care should be taken during this stage of data 
analysis to avoid wrong comparison between spectral data.70 One of the commonly used 
normalisation technique is to set the total spectral area to a constant sum, known as area 
normalisation. Area normalisation compensate for the differences in sample weights and 
concentration. Other commonly used normalisation techniques are range normalisation 
and normalisation to a “housekeeping” metabolite.70 The variation in pH, temperature 
and intermolecular interactions results in misalignment of peaks in MR spectra.
Alignment of spectral peaks is an important step before multivariate analysis. Several 
peak alignment algorithms are used to achieve a properly aligned spectral data.71
Commonly employed peak alignment techniques for MR spectra includes interval 
correlated shifting (icoshift)72, correlation optimized warping (COW)73 and parametric 
time warping (PTW).74
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1.3.2 Principal component analysis (PCA)
PCA is a commonly used non supervised technique for multivariate data exploration.75
It reduces the dimensionality of the data and reveals the hidden structure within a 
dataset. The variance structure of the data is explained through linear combinations of 
the variables called principal components (PCs). The first PCs will be in the direction 
explaining most of the variance in the data set. In the score plot of the PCA, samples 
with a similar metabolic profile will cluster, while the corresponding loading profile 
displays the importance of each variable within the PC.
1.3.3 Partial least squares (PLS)
Partial least squares is a supervised analysis method used to identify the fundamental 
relations between two matrices, usually the spectral data X and the clinical outcome or  
some other sample characteristics Y.75 Similar to PCA, PLS is also a linear 
decomposition technique while it differs in the optimization problem that is solved to 
find a projection matrix. PLS finds projection directions for which the covariance 
between the data matrix or predictor variables, X, and the responses, Y is maximized.
PLS models can be interpreted in a similar way as PCA models using the scores and
loadings plots. PLS Discriminant Analysis (PLS-DA) consists of a classical PLS 
regression where the response variable is a categorical one and expresses the class 
memberships.
1.3.4 Multilevel analysis
In metabolic studies where the metabolic changes of interest are subtle compared to the 
between subject variation, it may be difficult to capture the relevant information. If the 
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interventions are performed on the same patient, it is possible to utilize the multilevel 
structure of the data to capture within subject variations.76 Multilevel PLS-DA
(MLPLS-DA) is used for paired comparisons of multivariate data. MLPLS-DA can be 
considered a multivariate extension of a paired t test that generates different multivariate 
submodels for the between-subject and within-subject variation in the data. This allows 
to split the variations and hence to analyse without being confounded by the other 
variation sources.
1.3.5 Validation
Validation of multivariate models is a crucial step to evaluate the performance and 
stability of the statistical model. This involves several techniques like cross validation, 
independent test sets and permutation testing. Using a separate independent test set 
with similar type of samples as used in the calibration set would be the ideal way for 
validation. However, in most of the real life situations, we have access to only a finite 
set of samples, usually less than what is wanted. Hence an approach called cross 
validation is used where the data is split into a training set and a test set. In a full cross 
validation (leave one out), only one sample is used for testing the model while all other 
samples are used to build the model. The process is repeated leaving one sample at a 
time for the whole dataset, and the average of the classification result is estimated. This 
is a convenient technique for small sample size (n~20) at the expense of overfitting and 
over optimistic results.77 Alternate approaches includes using random subsets (a small 
percentage of the whole data) to test the model.
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A permutation test is used to assess the statistical significance of the classification 
results.78 During this process the class labels are randomly assigned to the samples. The 
classification result is calculated after the permutation and after repeating the process 
several times (typically >1000).79 The classification error distribution from the model 
using permuted classes can be compared with the original model to assess the 
significance of the model.
1.4 Biomarkers
Recently, biomarkers have gained wide attention among the scientific community and 
clinical practice. Clinicians are always in need of tools to aid in better patient 
management, and valid biomarkers can significantly help in risk stratification, effective 
prognostication and to effectively treat patients with diseases. A consensus panel at the 
National Institutes of Health standardized the definition of a biomarker in 2001 as ‘a 
characteristic that is objectively measured and evaluated as an indicator of normal 
biological processes, pathogenic processes, or pharmacologic responses to a therapeutic 
intervention or other health care intervention’.80 A biomarker can be measured in 
biological samples (like serum, tissue or urine), it can be recorded (like blood pressure, 
Electro cardiogram) or it can be a parameter derived from an imaging test like MR or 
CT scan.
Potential usefulness of biomarkers can range along the whole spectrum of the disease 
process. Prior to diagnosis, they can be used for screening and risk assessment. On the 
other hand, during diagnosis, biomarkers can aid in staging, grading, and selection of 
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initial therapy. During therapy, they can be useful in monitoring therapy, selecting 
additional therapies, or in monitoring recurrence.
1.4.1 Characteristics of an ideal biomarker
Optimal patient management is the key expectation out of a biomarker. A biomarker
will be of clinical value only if it is accurate, reproducible, acceptable to the patient, 
easy to interpret by clinicians, and has high sensitivity and high specificity. A new 
biomarker should prove its ability in multiple studies by showing its ability to explain
the outcomes independent of the established predictors in a consistent pattern. There 
should be validation data to suggest that knowledge of biomarker levels can change the 
patient management. During validation, performance characteristics like sensitivity, 
specificity and reproducibility of the biomarker must be evaluated. 
The clinical value of a biomarker depends on its accuracy, reproducibility of the 
measurements, and patient compliance. The intended use of a biomarker may affect the 
desirable characteristics of a biomarker. For biomarkers indicating disease progression 
or treatment response, sensitivity or specificity are less important compared to screening 
biomarkers because the patient serves as his or her own control.81 Similarly, costs may 
be less important for prognostic markers because only people with the disease are 
tested.
The course of biomarker development faces complex challenges and uncertainty. Most 
of the current biomarkers do not satisfy the required characteristics. Validation and 
demonstration of clinical utility of new biomarkers needs generation of prospective 
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data. If a biomarker is to be used as a surrogate endpoint, it needs the highest level of 
evidence to prove that the marker accurately predicts the clinical endpoint of interest in 
well-designed studies.82
Table 1.2: Biomarker Validation and Qualification
Type of 
Biomarker
Definition Purpose
Exploration Research and development 
tool
Hypothesis generation
Demonstration Probable or emerging 
biomarker
Decision making, supporting evidence 
with primary clinical evidence
Characterization Known or established 
biomarker
Decision making, dose finding, 
secondary/ tertiary claims
Surrogacy Biomarker can substitute for 
a clinical endpoint
Regulatory approval
NOTE: Shown are four categories of biomarkers used for drug development and their 
intended purpose.
SOURCE: Adapted from Wagner, 2006.83
In a complex and heterogeneous diseases like cancers, it is unlikely that a single 
biomarker can detect all the subtypes and stages of the disease with optimum sensitivity 
and specificity. Combining several biomarkers could be a way to improve the sensitivity 
of diagnostic markers. Multiple biomarker panels have been tried in cardiovascular risk 
assessment and in ovarian carcinomas with improved results.84,85 The four main 
categories of biomarkers used for drug development and their intended purposes are shown 
in Table 1.2.
Recent advances in molecular biology and development of microarrays, proteomics, 
metabolomics and nanotechnology has opened up new opportunities in the biomarker 
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development. A system biology based approach with cross collaboration between 
biologists, clinicians, chemists, computer scientists have greatly improved our ability to 
retrieve, analyse and characterize huge amount of data generated by the various –omic 
platforms. These approaches also focus on the multiple components of the deranged 
regulatory networks and uses multi parametric analyses to detect intricate 
derangements. Compared to a single biomarker or pathway analysis, this multi-
parametric approach may provide better insight in to diagnosis, prognosis and 
treatment.86
1.4.2 Metabolomics in biomarker development
The development and application of novel “omics” technologies are directly related to
the recent growth in biomarker discovery. Metabolomics allows simultaneous and 
parallel assessment of the metabolites present in cells, tissues and biofluids and helps to 
capture the alteration in the biochemistry associated with pathologies. The process of 
biomarker discovery involves different phases ranging from preclinical exploration to 
clinical use and disease control.87 The first step in metabolic biomarker search often 
begins with preclinical studies, comparing tumor tissue with non tumor tissue. These are 
exploratory studies to identify characteristics unique to tumor tissue that might lead to 
ideas for clinical tests for detecting pathologies like cancer. Key objectives of different 
phases in biomarker discovery are depicted in Table. 1.3. Most of the work in this thesis 
involves the first phase in biomarker search.  
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Table 1.3: Five Phases of biomarker development- from discovery to delivery (adapted from 
Pepe et al,87 with permission from Oxford University Press)
Description Phases Objective
Preclinical 
Exploratory   
PHASE 1 Identify promising directions & feasibility
Clinical Assay and 
Validation
PHASE 2 Clinical Assay to Detect established Disease
Retrospective 
Longitudinal
PHASE 3 Case-control studies using repository 
specimens
Prospective 
Screening
PHASE 4 Longitudinal studies to predict disease
Disease Control PHASE 5 Clinical use
Although metabolomic studies of human diseases in the last decade have discovered a
number of novel biomarkers, none have currently made the transition to routine use in
clinical practice.39 Metabolites identified from these early studies will need to form the 
basis of larger, prospective, externally validated studies in clinical cohorts for their
future use in the clinics.
1.4.3 Metabolomics in cancer biomarker development
Biomarkers have a potential role in clinical medicine for prognostic and predictive 
purpose. Several exploratory studies are done on cell cultures, experimental animals for 
evaluating metabolic biomarkers for cancer diagnostics followed by their evaluation in 
tumour tissue or biofluids.88 Standard metabolomics experiments has shown that many 
tumors in general have elevated phospholipids, increased glycolytic activity, 
28
Introduction
channelling of glycolytic carbon for synthetic  activity, and high glutaminolysis.25,89,90
Metabolomics has been successfully used in breast and prostate cancer studies to detect 
changes in choline metabolites and glycolytic products.91-93 Similarly, metabolomics 
studies in brain tumors and ovarian tumors have shown metabolic biomarkers of 
potential clinical value.94-96 However, there are still several missing links in the 
knowledge about the tumor metabolome and the metabolic profiles vary among distinct 
tumor types making it difficult to generalise the findings among tumor groups.68
1.4.4 Metabolomics in cardiovascular health
Prognostic markers of adverse cardiovascular outcomes like low density lipoprotein 
(LDL) cholesterol are popular even among the general public. Diagnostic markers of 
acute changes like troponin I and troponin T are widely used to aid the diagnosis of 
myocardial infarctions. There is always a compelling need for identifying biomarkers of 
cardiovascular fitness, which can detect the adverse changes at a very early stage of the 
pathogenesis. Metabolomic studies have been used in experimental and epidemiological 
studies with the aim of detecting biomarkers of cardiac health. In patients with 
hypertrophic obstructive cardiomyopathy undergoing “planned myocardial infarction”, 
metabolic profiling of the plasma samples revealed metabolic changes as early as 10 
minutes following the procedure.19 In a normal physiological context, exercise related 
metabolic changes are detected in the plasma of individuals running on a treadmill.97
There are several studies which explored the metabolites in blood plasma associated 
with inflammation, oxidative stress and lipid metabolism, which are key mediators in
CVD pathogenesis.98-102 Although the application of metabolomics in the clinics is still 
29
Introduction
in its infancy, it is a powerful technique to address complex tasks such as cardio-
vascular risk assessment, treatment response monitoring and patient management.
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2 Thesis Objectives
The main objective of the research presented in this thesis was to evaluate the use of 
high resolution MRS together with multivariate analysis based metabolomic pipeline for 
identifying and characterizing potential biomarkers of health-disease continuum. In
more detail:
1. To investigate metabolic differences between healthy individuals with high and 
low aerobic fitness (VO2max) by MR metabolomics, and further to describe these 
differences qualitatively and quantitatively.
2. To characterize the metabolic profile of astrocytomas with ex vivo HR-MAS 
MRS and to establish MRS markers to distinguish WHO grade II (A-II) and 
grade IV astrocytomas (glioblastomas; GBM) at a metabolic level and to assess 
the correlation between MR spectral profiles, baseline patient characteristics, 
and preoperative magnetic resonance imaging (MRI)-defined tumor volume.
3. To identify the metabolic differences between ovarian serous carcinoma 
effusions obtained pre- and post-chemotherapy, as well as to compare ovarian 
carcinoma effusions with breast carcinoma and malignant mesothelioma 
specimens.
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3 Materials and methods
3.1 Patients and data sets
In paper I, all the subjects were healthy people from the Nord-Trøndelag Health Study 
(HUNT3) in Norway, which was carried out between 2006 and 2008. Among 50,821 
participants in HUNT3, 4631 healthy, adult subjects attended a sub-study called the 
Fitness Study, designed to measure VO2max.103 From the Fitness Study-population, 220 
individuals between 40 and 59 years were selected pair-wise with one having low and 
the other high VO2max (selected from top or bottom 15 subjects within each age-year), 
but otherwise same gender, equal age in years, same physical activity index score 
(within 15% difference) and equal time since last meal. Subjects were ranged according 
to VO2max reported as mLڄkgíڄminí, and maximum five pairs of subjects were 
matched from each age-year. Two subjects did not provide a blood sample, and the 
study thus included 218 subjects (45 males and 63 females in the low VO2max-group, 
and 46 males and 64 females in the high VO2max-group).
The study cohort in paper II was 58 patients (median age, 57 years; range, 27-81 years; 
27 female, 31 male patients) with histologically verified supratentorial, diffuse 
astrocytomas (48 glioblastomas and 10 A-IIs). Preoperative functional status of the 
patients was evaluated with the Karnofsky Performance Status Scale.104 Preoperative 
MRI was used to determine tumor volumes. Tumor volumes were estimated with an
ellipsoid volume formula (ସଷ ߨݎଵݎଶݎଷ) based on the maximum tumor diameters in the 
perpendicular dimensions as described elsewhere.105,106 All surgeries were performed 
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under general anesthesia with an ultrasound-based neuronavigation system. Patient and 
tumor characteristics are presented in Table 3.1
Table 3.1: Baseline characteristics
Parameter GBM A-II
Patientsa 48 10
Median (range) age (years) 58 (27-81) 47 (29-71)
Gender(female/male) 25/23 2/8
Preoperative KPS KPS 90-100  10%
KPS 70-80    61%
KPS <70       29%
KPS 90-100    64%
KPS 70-80      27%
KPS  <70        9%  
Recurrent Tumor 17b 2
Abbreviations: GBM, glioblastoma; A-II, WHO grade II astrocytoma
Note: Recurrent Tumor denotes that the patient has been operated earlier. For patients 
with GBM, this means that they have been operated for either an A-II or GBM 
previously. Four among 17 recurrent GBM has a previous histology of A-II.
aUnless otherwise indicated, values are numbers of patients.
bFour of the glioblastomas were secondary, i.e. previous histology was A-II.
In paper III, the samples comprised of pleural and peritoneal effusions from 95 patients 
diagnosed with ovarian carcinoma, 10 with breast carcinomas, and 10 with malignant 
mesotheliomas. Among the ovarian carcinomas, 8 were paired peritoneal specimens 
obtained pre- and post-chemotherapy from the same patient. All these specimens were 
submitted to the Norwegian Radium Hospital, Oslo, Norway from 1999-2012.
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All studies were approved by the Regional Committees for Medical and Health 
Research Ethics, and written informed consent was obtained from all included patients.
3.2 Sample handling
For paper I, which is focusing on serum markers of aerobic fitness, venous non-fasting 
blood samples were collected in serum-tubes with no additives. The blood was 
centrifuged at 3000 rpm for 10 minutes approximately 1 hour after sample collection. 
7KHVHUXPVDPSOHVZHUHVWRUHGDWí&LQWKHHUNT biobank at Levanger, Norway
until being used for metabolic profiling. Before analyses, the serum samples were 
slowly thawed at 4°C. Aliquots of 150 μL were mixed with equal amounts of buffer 
solution (Na2HPO4 ×7H2O (0.075M), 4% NaN3 in H2O (5ml, mass % of NaN3 versus 
mass % of H2O), TSP (3-(trimethyl-silyl) propionic acid-d4, 0.4g), D2O (100 mL), pH 
adjusted to 7.4 with 1M HCl (1M NaOH), filled up to 500 mL with H2O) and 
transferred to high-quality 3 mm MR tubes. The ratio between H2O and D2O was 90:10 
in all samples.
Paper II deals with tissue samples from brain tumors. During surgery, tumor biopsies 
for this study were put in cryogenic vials within a median delay of 60 seconds and snap-
frozen in liquid nitrogen (-196 ºC). Separate biopsies from the same tumor area were 
sent for routine histological analysis. All samples to be analysed by HR-MAS
were stored in a cryogenic tank to prevent biochemical degradation until analysis.
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Samples in paper III were biofluids from pleural and peritoneal effusions. Effusions
were submitted for routine diagnostic purposes and were processed immediately after 
tapping. Effusion specimens were centrifuged, and supernatants were frozen at -70°C.
Subsequent treatments were similar to the serum samples in paper I
3.3 MRS protocol
3.3.1 MRS of biofluids
The MR spectra were acquired using a Bruker Avance III 600MHz/54 mm US-Plus 
(Bruker Biospin, Rheinstetten, Germany) operating at 600 MHz for proton (1H), 
equipped with a QCI cryoprobe. All spectra were recorded in an automatic fashion 
using a Bruker SampleJet and the ICON-NMR software (Bruker Biospin, Rheinstetten, 
Germany). Proton spectra were obtained at a constant temperature of 300 K (27ºC) 
using a modified Carr-Purcell-Meiboom-Gill (CPMG) pulse sequence with 
presaturation during the relaxation delay (cpmgpr1d; Bruker Biospin pulse sequence
library) to achieve water suppression and to facilitate the detection of low molecular 
weight species by avoiding the large overlapped signals derived from large molecules 
such as proteins and lipids. The spectra were collected with 64 scans and 4 dummy 
scans. The acquisition time was 3.067 seconds, measuring the FID via collection of 32K
complex data points resulting in a spectral width of 20.0363 ppm. A relaxation delay of 
4 seconds was used, during which presaturation at 25 Hz was applied. The receiver gain 
was kept at a constant value of 90.5 and the effective echo time was 80ms. The FIDs 
were Fourier transformed after exponential line broadening of 1 Hz. For metabolite 
quantification, nuclear overhauser effect spectroscopy (“noesy”, Bruker Biospin pulse 
sequence library: noesygppr1d) spectra were acquired using 32 transients with four 
36
Materials and methods
dummy scans, 96 K points per spectrum giving an acquisition time of 2.72 seconds and 
a mixing time of 10 ms, and apodized using an exponential line broadening parameter 
of 1Hz, and a 4 seconds recycle delay. Measurement and processing was done in full 
automation using Bruker Biospin standard automation programs controlled by ICON-
NMR (along with TopSpin v3 patchlevel 3, Bruker Biospin, Rheinstetten, Germany).
3.3.2 MRS of tissue samples
The HR-MAS experiments were performed with a Bruker Avance DRX600 
spectrometer with a 1H/13C HR-MAS probe (Bruker BioSpin GmbH, Rheinstetten, 
Germany) with magnetic field gradients aligned with the magic angle axis. Before the 
HR-MAS experiments were performed, tumor tissues were sliced to fit 30-mL leak-
proof disposable inserts (Bruker Biospin Corp, Billerica, Massachusetts) filled with 
phosphate-buffered saline buffer (3 mL of a mixture of TSP [4.5 mmol/L], sodium 
formate [20 mmol/L] and D2O-based phosphate buffered saline). Sample preparation 
was performed on an ice block to maintain a low-temperature working atmosphere. The 
inserts were further placed in zirconium MAS rotors (4mm). Mean ± SD sample weight 
was 7.7 ± 3.4 mg. All spectra were acquired at spin rate of 5 kHz and at 4oC to 
minimize tissue degradation. Proton spectra were acquired with a spin-echo Carr-
Purcell-Meiboom-Gill sequence (cpmgpr; Bruker Biospin pulse sequence library) with
3-second water suppression before a 90o excitation pulse. T2 filtering to suppress broad 
resonances from lipids and macromolecules was obtained with an effective echo time of 
32 ms. With an acquisition time of 1.64 seconds, 128 transients were collected over a 
10-kHz spectral region containing 32K points, giving a repetition time of 4.64 seconds.
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Phosphorous HR-MAS experiments were performed with a Bruker Avance III 600 
MHz/54 mm US spectrometer with a 1H/13C/31P HR-MAS probe (Bruker BioSpin 
GmbH, Rheinstetten, Germany). 31P HR-MAS spectra were acquired with a spin rate of 
5 kHz at 4 o C with the use of a 1-dimensional power-gated sequence with 1H
decoupling (zgpg; Bruker Biospin pulse sequence library). With an acquisition time of 
0.67 seconds, 512 transients were collected (repetition time = 2.67 seconds) over a 24-
kHz spectral region containing 32K points.
3.4 Data analysis
All multivariate analyses in this thesis were performed with MATLAB (version 7.9.0; 
The Math Works, Natick, Massachusetts) and PLS_Toolbox version 5.8.3 (Eigenvector 
Research, Manson, Washington). The spectra were peak aligned with icoshift.72 PASW 
Statistics 17.0 (IBM, New York) was used for traditional statistical analyses. All 
statistical tests were two-sided, and p-values below 0.05 were considered statistical 
significant. Kolmogorov-Smirnov test was used to test for normality. One-Way 
ANOVA was used for comparing variables between the high and the low VO2max-
groups, and the Kruskal-Wallis test was used in non-parametric analyses. Results are 
given in mean ± SE. Pearson’s correlation was used to study associations between 
normally distributed variables, and Spearman’s correlation was used in non-parametric 
analyses. 
3.5 Clinical diagnostics and Histopathology
Weight and height of subjects in the HUNT study (Paper I) were measured on a 
combined scale (Model DS-102, Arctic Heating AS, Nøtterøy, Norway), and BMI was 
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calculated as weight divided by height squared (kg mí). Blood pressure and resting 
heart rate were both measured while sitting (Critikon Dinamap 845XT, GE Medical 
Systems, Little Chalfont, Buckinghamshire, United Kingdom) and followed established 
guidelines.107 An individualized protocol was applied to measure VO2max treadmill 
running to exhaustion.108 The VO2max-test was performed using a ramp protocol where 
the speed was constant and the incline was increased with 2% every second minute until 
VO2max was reached. All clinical-chemical analyses for the paper I was performed on 
fresh venous non-fasting blood samples at Levanger Hospital, Norway.
For routine histopathological analyses in paper II, resected astrocytoma tissue was fixed 
in buffered formalin and embedded in paraffin wax, and 5-mm-thick sections were cut 
and stained with hematoxylin, eosin, and saffron. An experienced neuropathologist 
examined all sections, and the astrocytomas were graded according to the latest WHO 
criteria into grades II to IV.33 After HR-MAS analyses, the sections were examined
microscopically to assess the fraction of tumor cells and necrosis. IDH1 expression 
status was evaluated using immunohistochemistry. Briefly, 5-mm-thick sections were 
incubated with the primary antibody (antihuman IDH1 R132H; Dianova, Hamburg, 
Germany; dilution, 1:10, incubation time, 30 minutes at room temperature) after 
quenching ofendogenous peroxidase activity with 3% hydrogen peroxide and antigen 
retrieval by pressure cooking. The immunostaining was carried out on a DAKO 
Autostainer (Dako, Glostrup, Denmark).
For the effusion samples in paper III, cell blocks were prepared using the Thrombin clot 
method. Diagnoses were established using morphology and immunohistochemistry. 
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Effusion specimens were centrifuged, and supernatants were frozen at -70°C. Smears 
and H&E-stained cell block sections were reviewed by a surgical pathologist 
experienced in cytopathology.
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4 Summary of papers
Paper I
Serum levels of choline-containing compounds are associated with aerobic fitness 
level: the HUNT-study.
Cardiovascular disease (CVD) is a leading cause of death worldwide, and the number of 
people at risk is continuously growing. New methods for early risk prediction are 
therefore needed to actuate prevention strategies before the individuals are diagnosed 
with CVD. Several studies report that aerobic fitness level, measured as maximal 
oxygen uptake (VO2max), is the single best predictor of future CVD mortality in healthy 
people. Based on this, we wanted to study differences between healthy individuals with 
a large difference in VO2max -level to identify new biomarkers of low aerobic fitness that 
may also have potential as early biomarkers of CVD. Serum samples from 218 healthy 
individuals with a low VO2max (n = 108, 63 women) or high VO2max (n = 110, 64 
women) were analysed with MR metabolomics. In addition, standard clinical-chemical 
analyses for glucose, lipids, liver enzymes, micro-CRP, and colorimetric analysis on 
circulating choline were performed. Individuals in the low VO2max -group had increased 
serum levels of free choline, decreased phosphatidylcholine, increased glucose and 
decreased unsaturated fatty acids compared to the individuals in the high VO2max-group.
Aerobic fitness dependent differences in serum levels of free choline and 
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phosphatidylcholine are observed. They should be further studied as potential early 
markers of CVD risk.
Paper II
Differentiating Diffuse World Health Organization Grade II and IV Astrocytomas 
with Ex Vivo Magnetic Resonance Spectroscopy.
The prognosis and treatment of astrocytomas, which are primary brain tumors, vary 
depending on the grade of the tumor, necessitating a precise preoperative classification. 
Magnetic resonance spectroscopy (MRS) provides information about metabolites in 
tissues and is an emerging non-invasive tool to improve diagnostic accuracy in patients 
with intracranial neoplasia. This study aims to investigate whether ex vivo MRS could 
differentiate World Health Organization grade II (A-II) and IV astrocytomas 
(glioblastomas; GBM) and to correlate MR spectral profiles with clinical parameters.
Patients with A-II and GBM (n = 58) scheduled for surgical resection were enrolled. 
Tumor specimens were collected during surgery and stored in liquid nitrogen before 
being analysed with high-resolution magic angle spinning MRS. The tumors were 
histopathologically classified according to World Health Organization criteria as GBM 
(n = 48) and A-II (n = 10). Multivariate analysis of ex vivo proton high-resolution magic 
angle spinning spectra MRS showed differences in the metabolic profiles of different 
grades of astrocytomas. A-II had higher levels of glycerophosphocholine and myo-
inositol than GBM. The latter had more phosphocholine, glycine, and lipids. A
significant metabolic difference between recurrent and nonrecurrent GBM (P < .001)
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was observed. Primary GBM had more phosphocholine than recurrent GBM. A 
significant correlation (P < .001) between lipid and lactate signals and histologically 
estimated percentage of necrosis was observed in GBM. Spectral profiles were not 
correlated with age, survival, or magnetic resonance imaging-defined tumor volume. Ex 
vivo MRS can differentiate astrocytomas based on their metabolic profiles.
Paper III
Proton magnetic resonance metabolomic characterization of ovarian serous 
carcinoma effusions: chemotherapy-related effects and comparison with malignant 
mesothelioma and breast carcinoma 
Malignant serous effusions are a common manifestation of advanced cancer, associated 
with significant morbidity and mortality. The aim of this study was to identify the 
metabolic differences between ovarian serous carcinoma effusions obtained pre- and 
post-chemotherapy, as well as to compare ovarian carcinoma (OC) effusions with breast 
carcinoma and malignant mesothelioma specimens. The supernatants of 115 effusion 
samples were analysed by high-resolution magnetic resonance (MR) spectroscopy in 
vitro and multivariate analysis. The samples comprised of pleural and peritoneal 
effusions from 95 OC, 10 breast carcinomas, and 10 malignant mesotheliomas. Among 
the OC, 8 were paired peritoneal specimens obtained pre- and post-chemotherapy from 
the same patient. OC had elevated levels of ketones (aceto-acetate and beta-
hydroxybutyrate) and lactate compared to malignant mesotheliomas and breast
carcinomas, whereas the latter had more glucose, alanine, and pyruvate. Multivariate 
analysis of paired effusions in OC showed a significant increase in glucose and lipid 
levels in the post-treatment spectra (P=0.039). MR spectroscopy is a promising 
43
Summary of papers
technique for comprehensive and comparative studies of metabolites in malignant 
serous effusions and our study shows that small metabolites associated with effusions 
might improve our understanding of tumor biology and disease progression and has 
diagnostic potential in this differential diagnosis.  
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5 Discussion
The main goal of this thesis was to evaluate the use of high resolution MR
metabolomics for identifying and characterizing potential biomarkers in the health-
disease continuum. Subjects in this thesis ranged from healthy volunteers (Paper I) to 
patients with advanced stage of malignancies (in Paper II and III). In the first study,
aerobic fitness dependent differences in serum levels of free choline and 
phosphatidylcholines in a group of healthy volunteers were observed. In paper II, the 
possibility of differentiating diffuse World Health Organization Grade II and IV 
astrocytomas based on their metabolic profiles were showed. Metabolic markers of 
chemotherapy related changes in ovarian serous carcinoma effusions were identified in 
Paper III. In addition, the metabolic portraits of ovarian carcinomas were compared with
breast carcinoma effusions and mesotheliomas in paper III. Throughout these studies, 
the utility of using a high resolution MR based metabolomics approach for biomarker 
discovery has been investigated. This thesis also evaluates the role of advanced
multivariate analysis techniques in deciphering the complex and multidimensional 
spectral data. In paper I and III, the samples were biofluids and its usability in detecting 
perturbations of endogenous metabolites in normal physiology (aerobic fitness, paper I) 
and pathology (malignant effusions, paper III) was explored. The extension of the MR
metabolomics technique to intact biopsy specimens from brain tumor patients was
evaluated in paper II, and potential markers for tumor grading and prognostication were 
identified. The usefulness of MR metabolomic techniques in capturing molecular 
signatures of complex pathologies like cancer has been explored (paper II, III). This 
may contribute further to the scientific understanding of the underlying tumor biology.
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5.1 Metabolic profiling for biomarker identification
MRS and mass spectrometry are the two main analytical techniques widely used in the 
study of metabolites in biological fluids and tissues from biopsy samples.65,109,110 MRS
offers a nondestructive and highly reproducible way for analyzing metabolites with 
minimal sample preparation. In all the studies included in this thesis, MR based 
metabolomics were used for metabolic profiling tissue or biofluids. All these studies 
generated snap shots of metabolic activity ranging from physiological (paper I) to 
pathological conditions (paper II and III). The complexity of the data was handled by
multivariate techniques. To identify the biochemical similarity between samples and to 
capture the metabolic patterns indicative of a particular physiological or pathological 
state, linear projection methods like PCA and PLS-DA has been utilized in all papers (I-
III). The usefulness of MRS based metabolomic for characterizing the biomarkers of 
clinical importance and to uncover disease mechanism has been evaluated in these 
studies.
Most of the works in this thesis are in the discovery or explorative phase of biomarker 
research. In an exploratory study, it is important to ensure that sample handling and data 
acquisition is optimized to maintain the stability of metabolites. Sample storage and 
preparation has to be optimal to avoid sample aging and degradation. In our study, all 
samples were stored and transported at very low temperatures (í& or í°C) to
ensure metabolite stability.111,112
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The process of biomarker discovery has a long path when it comes to real clinical 
translation of the findings. The quality of the initial sample set is vital in determining 
the sensitivity, specificity, accuracy of biomarkers and the success rate of clinical 
translation. Often the term “differentiating metabolite” is more appropriate than the term 
biomarker for describing the metabolic markers identified in the exploratory phase of 
the biomarker discovery.113 There is always a need for a multistep qualification process 
with rigorous assessment of precision, accuracy and diagnostic or prognostic value. In 
addition, it is also beneficial to have additional scientific evidence showing the link 
between a candidate biomarker and the pathophysiology of interest. 
MR metabolomics is a useful technique to identify the biochemical signatures of 
physiology and pathology. The potential use of metabolomic biomarkers can range 
widely from screening, prognostication and prediction of disease recurrence to
evaluation of treatment related changes. The different studies covered in this thesis have 
explored the potentials of metabolomic techniques in clinical (paper II and III) and in 
population based studies (HUNT study, paper I). A summary of potential metabolic 
biomarkers identified in this thesis are shown in Table 5.1
5.2 Analysis of metabolomic data
In all the papers included in this thesis, multivariate data analysis techniques played an 
important role in extracting the knowledge from the high dimensional MR spectral data.
PCA and PLS-DA were used in paper I and II whereas in paper III, MLPLS-DA was 
also added to utilise the multilevel structure of the data. Since a single biomarker is 
often insufficient and nonspecific for a given condition, multivariate methods are of 
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special importance in metabolomics.114 One of the advantages of multivariate 
techniques is the ability to use the whole spectra as an input for analysis, without the 
need for metabolite quantification. Although metabolite quantification is helpful in 
detailed understanding of metabolic complexities and for determining characteristic 
biomarkers, quantitative MRS of biological samples poses several challenges. High 
degree of overlap in the (peaks obtained from) MR spectra of biological sample makes 
it difficult to precisely quantify the metabolites. 32,115 The techniques such as peak 
fitting are more useful in targeted metabolomic studies than non-targeted exploratory 
studies and are often subjective and time consuming. Absolute metabolic quantification 
needs a stable reference compound which is added to the sample (external reference) or
present inside the sample (internal reference). Using TSP as a reference is limited as it 
binds to proteins in the tissue samples/biofluids. Using a relative quantification 
approach based on metabolite ratio is often used. Ratio based approaches can be 
affected if there exists a positive correlation between the metabolites. In this thesis, 
being a non-targeted and exploratory phase of biomarker research, only multivariate 
techniques are used.
By using the whole spectra, multivariate techniques can identify the patterns of 
metabolites which are linked with the conditions or disease under study. The 
multivariate models used in this thesis are all linear models and allows the interpretation 
of the metabolites which are responsible for the discrimination between the study 
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Discussion
groups. This is important in biomarker studies which are in the exploratory phase so that 
they can contribute towards improving the biological insights and in possible 
identification of treatment targets. All PLS-DA models were cross validated to achieve 
reliable classification results. The classification accuracy was further evaluated using 
permutation testing to rule out spurious discoveries from random classifications.
The use of multivariate paired data analysis to capture chemotherapy related changes in 
the metabolic composition of serous effusions was explored in Paper III. In this 
analysis, the advantage of the multilevel structure of the data has been considered. This 
method uses the net difference before and after chemotherapy as the input for 
multivariate analysis so as to examine the treatment related variation. This technique is 
useful to detect the metabolic changes related to treatment which are more subtle than 
the larger variation between the patients.
5.3 Serum markers of aerobic fitness
In this study, the metabolic patterns related to aerobic fitness in a group of healthy 
individuals (218 subjects) using high resolution MR metabolomics of the serum samples
were explored. The results showed that individuals with low VO2max had decreased
serum levels of phosphatidylcholine, increased choline and decreased unsaturated fatty 
acids compared to the individuals in the high VO2max group. VO2max being a single best 
predictor of future cardio-vascular disease related mortality, the indicators of low 
aerobic fitness may have a potential role in early CVD risk prediction.9,11-13 Previously, 
metabolomics studies using plasma and serum samples have been successfully utilized 
to detect biomarkers associated with clinical conditions such as coronary artery disease
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and myocardial infarction.17,19,116 However, there is a scarcity of evidence on the link 
between serum metabolites and cardiovascular fitness. In this study, serum samples 
from a group of healthy volunteers were investigated for markers of aerobic fitness. To 
account for the age, gender, physical activity and fasting status dependent variations in 
the metabolites, the participants were thoroughly matched.
Elevated levels of serum free choline have previously been associated with metabolic 
syndrome with a cluster of CVD risk factors.117 This may indicate that, elevated levels 
of cholines in the low VO2max group may have importance in future CVD risk 
prediction. This needs to be evaluated in future studies. Such early markers of risk 
prediction may have value in actuating preventive strategies at an earlier stage. As there 
is a switch in the levels of choline- phosphatidylcholine metabolites between the two 
groups, there might be differences in the choline biosynthesis or breakdown systems in 
the body in relation to aerobic fitness. Previously, it was shown that phospholipase D 
(PLD) activity, an enzyme linked with choline synthesis has been elevated in patients 
with atherosclerosis, hypertension, oxidative stress and inflammations.18 PLD catalyses 
the hydrolysis of PtdCho to phosphatic acid, releasing free choline. A high PLD activity 
in healthy subjects with low aerobic fitness can be speculated and needs further 
evaluation. In addition to changes in the levels of choline containing compounds, 
spectral profiles also indicated a decreased amount of unsaturated fatty acids in subjects 
with low aerobic capacity. Associations between low serums levels of unsaturated fatty 
acids have previously been associated with CVD risk.118
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There were certain limitations in this study. It would have been ideal to get a blood 
sample after overnight fasting to avoid the effect of chylomicrons from the circulation 
to have a more detailed overview of the lipids and lipoprotein subclass.119 However, a 
longer fasting time is difficult to accomplish in a population-based large-scale study 
which involves VO2max measurement. Future studies should be conducted on 
phosphatidylcholine and free choline to validate their potential as early markers of CVD 
and predictor of VO2max. This may help in actuating preventive strategies like life style 
modifications at an early stage in the pathogenesis of CVD.
5.4 Characterization of astrocytomas
In paper II, the potential use of MRS in differentiating stage II astrocytomas from stage 
IV astrocytoma (glioblastoma) has been addressed. Compared to paper I and III, this 
study involved tissue samples and are therefore analysed by magic angle spinning MR
based metabolomics. Multivariate analysis of the spectral data showed higher level of 
glycerophosphocholine and myo-inositol in grade II astrocytomas and higher levels of 
glycine, lipids and phosphocholine in grade IV astrocytomas. Further, there were 
significant metabolic differences between recurrent and non-recurrent gliomas. 
Histological estimates of necrosis in glioblastomas correlated with the levels of lipids 
and lactate. Moreover, the oncometabolite 2-hydroxyglutarate was detected in the HR-
MAS spectra and was associated with IDH mutation.
Previously, MRS has been used in neurooncology for differentiating brain tumor types, 
for drug development, response monitoring, and prognosis prediction.120-126 The total 
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choline (tCho) signal has been suggested as a biomarker for predicting cancer in vivo
and is elevated in brain tumors compared to normal brain tissue.25,123,127 Results from 
paper II shows that, HR-MAS at higher field strengths provides detailed information on 
cholines and resolves the tCho signal to GPC, PCho and free choline. The usability of 
ex vivo, high resolution MR metabolomics in identifying and establishing MR 
biomarkers of tumor grading has been evaluated. The importance of resolving GPC and 
PCho in discriminating different grades of astrocytomas was confirmed in this 
study.128,129
Abnormal choline metabolism associated with oncogenesis and tumor progression is an 
emerging metabolic hallmark of cancer.25 Increased expression of genes encoding 
choline kinase and choline transporters, and a reduction in phospholipase C gene 
expression has been observed in high grade gliomas.129 This may possibly explain the 
high PCho levels in glioblastomas. The balance between synthesis and degradation of 
choline metabolites determines the GPC/PCho ratios. Alteration in choline metabolites 
can also be linked to changes in tumor microenvironment such as hypoxia and acidic 
pH.25,26 Noninvasive assessment of choline metabolites by MRS allows discrimination 
of tumor grades and can have a potential role in assessing treatment response.130,131 In
our study, two different types of astrocytomas were differentiated based on their 
metabolic profiles. Furthermore, the potential role of phosphorous MRS in improving 
the detection of GPC and PCho on a pilot basis was explored. These findings may offer 
a unique translational possibility of using these individual choline metabolites in in vivo
characterization of diffuse astrocytomas. Advances in MRS techniques and improved 
field strength can tackle the problems like low sensitivity of phosphorous MRS in
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vivo.132-134 The clinical feasibility of detecting phosphorylated brain metabolites has 
been proved in pilot studies on patients with brain tumors.134 In addition to tumor grade 
dependent differences in metabolic profiles, a metabolic difference between recurrent 
and non recurrent glioblastomas was present. Recurrent glioblastomas had lower PCho 
levels than non-recurrent glioblastomas, probably reflecting the radiotherapy and/or 
chemotherapy related changes. This could also be due to difference in the choline 
metabolism between recurrent and non-recurrent glioblastomas. However, this needs 
further exploration as the process of glioma progression is a complex event which 
involves evolution of oncogenes and tumor suppressor genes over a period of time in a 
changing tumor micro environment.
Recently, IDH mutations are gaining wider attention in the context of gliomas. This is 
due to the improved life expectancy in glioma patients harboring this mutation.135,136 A
mutant IDH gene results in an altered enzyme which produces 2-hydroxyglutarate (2-
HG) from alpha-ketoglutarate.137 This newly produced 2-HG or oncometabolite is 
scarce in non-mutants and can be non-invasively detected using MRS. Hence it can be a 
non-invasive biomarker for sub-classification of glioma by identifying patients with 
improved prognosis. In our study (paper III), this oncometabolite was detected in the 
majority of the samples with IDH mutation (5 out of 8). This shows that, probing for 
MR detectable biomarkers at higher field strength helps to establish MR detectable 
markers for potential in vivo translation with improvements in MR equipments and 
pulse sequences. Still, it should be kept in mind that sensitivity limitations in MR is 
often an obstacle in the clinical translation of the findings.
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One of the main limitations of this study was the small number of patients. The findings 
in this study need to be confirmed in a larger patient cohort. As in most of the 
metabolomic marker research, this study too is in the initial exploratory phase or the 
phase I of the biomarker development. Astrocytomas are highly heterogenous, 
especially the glioblastomas, and this can results in overlaps in the multivariate 
classifier. In this study we were unable to recruit patients with anaplastic astrocytoma 
(WHO grade III); and future studies including them will aid in a broader comparison 
among grade II, III and IV. There are certain limitations which are inherent to ex vivo
studies.  Despite the possibility of detecting higher number of metabolites ex vivo,
studies are vulnerable to metabolic changes which may occur in connection to the 
biopsy procedure, transportation and experimental process and sample storage. It has 
been shown that snap freezing can minimize the metabolic changes from sample 
handling111, and in this study all samples were snap-frozen. Furthermore, previous 
studies have shown that high resolution ex vivo HR-MAS spectra can be directly related 
to in vivo proton MRS for metabolites like creatine, total choline, N-acetyl aspartate, 
myo-inositol and lipid signals (1.3 and 0.9 ppm) which are not likely to change within 
an extended ischemic period during surgery.112,138 Another potential issue associated 
with HR-MAS is the sample degradation that may result from sample spinning. To 
minimize this issue, we kept the sample spinning for less than one hour. There were two 
samples out of 58 with sub optimal morphology after HR-MAS experiment. However, 
those samples still had a large number of intact tumor cells for performing histo-
pathological examination after HR-MAS. Despite these limitations, this ex vivo
metabolic profiling of tumor tissue samples provided a wealth of knowledge and insight 
which might be helpful in the future studies for finding in vivo markers that can be 
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accurate surrogates for pathological classification of astrocytomas in a non-invasive
way.
Metabolic profiling using HR-MAS together with multivariate analysis is a useful 
technique in characterizing and identifying metabolic markers linked with different 
grades of astrocytomas. The potential role of different MRS technique such as 
phosphorous MRS in improving the discrimination between GPC and PCho, the most 
important choline metabolites associated with different grades of astrocytoma, has been 
explored. A comprehensive approach which incorporates various techniques like 31P
MRS, proton MRS, and molecular markers like IDH1 may add a new dimension to 
classification and management of astrocytomas. 
5.5 Metabolic portraits of malignant serous effusions
Metabolic differences between ovarian serous carcinoma effusions obtained pre- and 
post-chemotherapy has been portrayed in paper III. Metabolic characterization of the 
malignant serous effusion from ovarian carcinomas was performed and the metabolic 
profiles were compared to serous effusions in breast carcinoma and malignant 
mesotheliomas. The use of high resolution MRS of biofluids coupled with multivariate 
analysis was evaluated. Furthermore, the study demonstrated the power of utilizing the 
multilevel structure of the data to capture chemotherapy related changes in 
metabolites.76
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MRS of effusion fluids has previously been used to differentiate benign and malignant 
peritoneal effusions.139 Metabolic profiling of biofluids as a diagnostic tool has several 
advantages such as noninvasive or minimally invasive sample collection and the 
possibility of collecting multiple samples over a time course, making it an ideal choice 
for clinical studies.57 In paper III, the role of high resolution MRS was evaluated in a 
rapid, non-targeted manner to identify metabolic biomarkers of diagnostic and 
therapeutic importance in supernatants of 115 effusion samples. The ovarian carcinomas 
had elevated levels of ketones (acetoacetate and beta-hydroxybutyrate (BHB)) and 
lactate compared to malignant mesotheliomas and breast carcinomas whereas the later 
had more glucose, alanine and pyruvate. Even though the exact biological basis is 
unclear, elevated levels of acetone, acetoacetate and BHB are observed in serum 
samples of early stage ovarian cancer and colorectal cancer.140,141 The growing energy 
demand by tumor cells can trigger lipolysis which may contribute towards the elevated 
levels of ketones.140 Effusions represent an advanced stage of malignancy (stage III and 
IV) and during the process of metastasis to serous cavities; malignant cells can remain 
viable while suspended in the effusion fluid. The effusion fluids provide a 
microenvironment for the tumor cells and helps in the exchange of nutrients and 
mitogenic factors;142,143 hence the metabolic composition of the effusion fluid may 
closely reflect the severity and invasiveness of the metastatic cells. MRS of the effusion 
fluids help to study the metabolic composition of the serous fluid in a global non-
targeted manner. Future targeted studies are needed to further understand the details of 
the underlying mechanisms of energy transfers and metabolic fluxes in malignant 
effusions.
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Post-chemotherapy samples showed an elevation of glucose and lipids with a reduction 
in BHB and lactate in the effusions. This may indicate a reduction in the number of live 
malignant cells or a change in tumor metabolism resulting in reduced glucose uptake 
from the medium. Treatment related reduction in glucose uptake has been shown in 
ovarian cancer cell lines (OVCAR-3) in response to cisplatin treatment in previous 
studies.144 Future studies targeting glucose uptake by malignant cells in effusion fluids 
as a tool for chemosensitivity evaluation is warranted. Evaluation of chemotherapy 
induced changes failed in non-matched samples indicating the importance of 
multivariate paired data analysis.
The small number of samples involved was also here a limitation to the study.  The 
small number of patient matched samples (8 pairs) precluded the analysis of association 
between clinical parameters such as treatment response and survival in relation to 
metabolic profiles. This study looked only at the metabolic profiles of the effusion 
fluids and a combined metabolic profiling which includes the tumor cells from patient 
matched ovarian carcinomas from different anatomical sites could be an area of future 
research.
5.6 Translational perspectives
The most important and ultimate objective of biomarker discovery is the translation of 
those biomarkers to clinical practice so that the result of the research will be useful for 
enhancing human health and well-being. With the development in “omics” 
technologies, there are thousands of scientific publications documenting potential 
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biomarkers for developing effective therapies and improving patient benefits. However, 
only a few biomarkers have been successfully validated for routine clinical use.145,146
There are several practical issues such as logistical and regulatory challenges for large 
scale validation studies, lack of robustness in analytical technologies and
standardisation of protocols used in clinical trials.146,147 Metabolomics based biomarkers 
are successfully used in screening neonates for inborn errors of metabolism.148
However, the number of metabolomic based tests excluding the inborn error of 
metabolism remains “zero”.149 The changes in the biomarker concentration are often 
subtle and distributed among several metabolites in many common complex diseases
compared to profound metabolic changes in inborn error of metabolism, making it 
difficult to develop a single, accurate test. There is a need for standardisation of 
protocols among different laboratories and biomarker discovery should move in to a 
large collaborative network of multidisciplinary team. There should be more clarity in 
the description of laboratory techniques and reporting of biomarker research.149,150
Metabolite reporting should shift from qualitative to quantitative analysis, with explicit 
description of changes in metabolite concentration than qualitative way, as in many 
current metabolic studies. The potential of biomarkers in improving patient 
management and quality of life is greater than several other areas of biomedical 
research. It is important to tackle these obstacles in translation of biomarker research to 
a clinically useful product.
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6 Conclusions and future prospects
Metabolic profiling of serum samples from healthy volunteers showed that choline 
containing metabolites are associated with aerobic fitness. Low VO2max was associated 
with elevated levels of free choline and decreased levels of phosphatidylcholine. We 
need to do further studies to identify the exact mechanisms behind this shift in 
choline/phosphatidylcholine profiles between high and low VO2max individuals. They 
should also be further studied as potential early markers of CVD risk.
The second study (Paper II) showed that HR-MAS based metabolic profiling of intact 
tissue samples from tumor biopsies could be a potential tool for differentiating different 
grades of astrocytomas. Resolving GPC and PCho from tCho is important in metabolite 
based discrimination of astrocytoma grades. No significant correlation was observed 
between metabolic profiles and baseline patient characteristics. Combined use of 
different MRS techniques like 31P MRS, 1H MRS together with molecular markers like 
IDH1 may help in classification and in moving towards a personalized management of 
astrocytomas. In vivo translation of these results still has a way to go. Clinically 
approved in vivo scanners operate at lower field strengths (1.5-3 T) compared with ex 
vivo spectrometers (in our case, 14 T); thus, the sensitivity is inherently lower. 
Significant progress is being made toward the use of 7-T MRI in the clinical setting, and 
the development of technologies requiring shorter scanning time will follow. Hence, 
clinical translation of our results for in vivo validations should be performed in the near 
future.
60
Conclusions and future perspectives
In the third paper, the differences in metabolic profiles of malignant serous effusion 
from different anatomical sites were detected, and metabolic features related to 
chemotherapy exposure were identified using MRS. Metabolic characterization by high 
resolution proton MR spectroscopy could be a promising technique to further 
understand the mechanisms of effusion development in malignancies and to target 
clinical intervention.
In summary, all studies in this thesis showed that MRS based metabolomics is a useful 
technique in characterizing potential biomarkers of physiology and pathology. MR 
metabolomics allows rapid exploration of physiological and pathologic changes in 
samples that can be obtained in a minimally invasive manner. The method is therefore 
suited for early identification of specific metabolites or as patterns within a metabolic 
profile.
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Abstract
Background: Cardiovascular disease (CVD) is a leading cause of death worldwide, and the number of people at risk is
continuously growing. New methods for early risk prediction are therefore needed to actuate prevention strategies before
the individuals are diagnosed with CVD. Several studies report that aerobic fitness level, measured as maximal oxygen
uptake (VO2max), is the single best predictor of future CVD mortality in healthy people. Based on this, we wanted to study
differences between healthy individuals with a large difference in VO2max-level to identify new biomarkers of low aerobic
fitness that may also have potential as early biomarkers of CVD risk.
Methodology/Principal Findings: Serum samples from 218 healthy individuals with a low VO2max (n = 108, 63 women) or
high VO2max (n = 110, 64 women) were analysed with MR metabolomics. In addition, standard clinical-chemical analyses for
glucose, lipids, liver enzymes, micro-CRP, and colorimetric analysis on circulating choline were performed. Individuals in the
low VO2max-group had increased serum levels of free choline, decreased phosphatidylcholine, increased glucose¸ and
decreased unsaturated fatty acids compared to the individuals in the high VO2max–group.
Conclusions/Significance: Aerobic fitness dependent differences in serum levels of free choline and phosphatidylcholine
are observed. They should be further studied as potential early markers of CVD risk.
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Introduction
Cardiovascular disease (CVD) is a leading cause of death
worldwide, and the number of people at risk is continuously
growing [1]. New methods for early risk prediction are therefore
needed to actuate prevention strategies before the individuals are
diagnosed with CVD. Aerobic fitness level, measured as
maximal oxygen uptake (VO2max), is a strong marker for
cardiac health. Large-scale epidemiological studies have dem-
onstrated that low VO2max is the single best predictor of future
CVD mortality both in healthy individuals and in patients with
CVD [2–6]. Based on this, more knowledge of the differences
between healthy individuals with a large difference in VO2max-
level will be of great interest to identify new biomarkers of low
aerobic fitness that may also have a potential as an early
biomarker of CVD risk.
Emerging metabolite profiling technologies have recently made
it possible to acquire ‘‘snapshots’’ of the metabolic processes at a
given point in time [7,8]. This methodology, termed metabolo-
mics, involves a high throughput analysis of small-molecular
metabolites that are downstream products of preceding gene
expressions and protein activity. Within systems biology, magnetic
resonance (MR) metabolomics has become one of the key
platforms, allowing rapid analysis of samples with minimal sample
preparation. The acquired metabolic profiles can be useful for a
better understanding of the metabolic perturbations associated
with health and disease.
Previously, serum and plasma MR metabolomics have been
successfully used in the detection of biomarkers associated with
various clinical conditions such as coronary artery disease and
myocardial infarction [9–11]. Serum metabolites such as citric
acid, threonine, and choline have previously been associated with
the incidence of CVD, but so far the evidence is sparse [9–11]. To
our knowledge, no previous study has searched for serum
metabolites associated with aerobic fitness level in a healthy
population. The aim of the present study was to investigate
metabolic differences between healthy individuals with high and
low VO2max by MR metabolomics, and further to describe these
differences qualitatively and quantitatively.
PLoS ONE | www.plosone.org 1 July 2012 | Volume 7 | Issue 7 | e42330
Results
The high and the low VO2max-groups, which were matched for
age, fasting time and level of self-reported physical activity, had
significantly different body weight, waist circumference, waist-to-
hip-ratio, body mass index (BMI), mean arterial blood pressure,
resting heart rate, non-fasting glucose, triglycerides, micro C-
reactive protein (CRP), alanine aminotransferase (ALAT) and
gamma glutamyl transferase (Gamma-GT), but not total choles-
terol (Table 1). Data from questionnaires revealed that the own-
reported health status was significantly better in the high VO2max-
group compared to the low VO2max-group (Table 2). Dietary
questionnaires indicated only differences in fruit and berry intake
between the two groups (Table 2).
MR spectra indicated differences between the metabolic profiles
of the high and low VO2max-groups (Figure 1A). Exploration of the
corresponding loading profiles (Figure 1B) and MR spectra
(Figure 2) showed that low VO2max-subjects had higher levels of
lipid methylene (-CH2-) protons (peak at 1.3 ppm), indicating
decreased amounts of unsaturated fatty acids in serum from the
low VO2max-subjects. The low VO2max-subjects also had lower
levels of phosphatidylcholine (PtdCho) (-N(CH3)3
+, peak at
3.24 ppm) (Figure 2). A permutation test showed that the
differences in the metabolic profiles between high and low
VO2max-subjects were highly significant (p,0.001). The model
created by the MR metabolomics analysis could predict whether a
subject has a low or high VO2max with a sensitivity and specificity
of 63% and 65%, respectively.
A subsequent colorimetric analysis to further study the
differences in choline-containing compounds showed that the
levels of free choline were significantly higher in the low VO2max-
group compared to the high VO2max-group (14.5761.55 vs.
10.1360.91 mM, p=0.017). The serum choline levels seemed to
correlate with the serum triglycerides levels (high VO2max-group,
r = 0.50, p,0.005 and low VO2max-group, r = 0.74, p,0.0001).
There was no correlation between free choline levels and fasting
status.
Replicate 1H MR spectra of serum with assignments of the main
metabolites are illustrated in Figure 3. The score plot (Figure 3)
clearly displays a larger inter subject variance compared to intra
subject variance, which indicates excellent reproducibility. To
further assess the agreement between metabolite levels obtained by
laboratory assays and MR, the glucose concentration obtained by
standard methodology were correlated with the MR signal
intensities (relative quantification by peak integration 3.90–
3.94 ppm) for glucose. The data showed strong correlations
(R2 = 0.83).
Discussion
The main findings of this study were that the subjects with low
VO2max had increased serum levels of free choline and decreased
serum levels of phosphatidylcholine (PtdCho) compared to subjects
with high VO2max. In human cells, the majority of choline is taken
up by the cells and conversed into PtdCho. Since the ratio of
choline/PtdCho is switched between the subjects with high and
low VO2max, there might be difference in one of the enzymes of
the plasma membrane, phospholipase D (PLD). PLD catalyzes the
hydrolysis of PtdCho to phosphatic acid (PA), releasing soluble
choline. High PLD activity and increased level of PA has
previously been associated with oxidative stress, hypoxia, inflam-
mation, atherosclerosis and hypertension (reviewed in [12]). In the
Table 1. A statistical overview of the participants in this study.
Variable Low VO2max-group High VO2max-group p-value
n mean CI n mean CI
Age 108 49.5 48.4–50.6 110 49.5 48.4–50.6 –
VO2max (mL?kg
20.75?min21) 108 93.9 90.9–96.9 110 138.0 133.4–142.7 –
Physical activity index score 108 3.7 3.4–4.0 110 3.7 3.4–4.0 –
Waist (cm) 108 93.6 91.5–95.7 110 86.3 84.6–88.1 0.0004**
Hip (cm) 108 103.8 102.4–105.3 110 100.1 99.2–101.1 0.0004**
Arm circumference (cm) 108 30.3 29.7–30.9 110 28.7 28.3–29.2 0.0004**
Weight (kg) 108 80.7 77.9–83.5 110 73.5 71.4–75.6 0.0004**
Waist-to-hip-ratio 108 0.90 0.88–0.91 110 0.86 0.85–0.87 0.0004**
BMI 108 27.5 26.8–28.3 110 24.8 24.3–25.2 0.0004**
Heart rate at rest 103 62.3 60.2–64.4 102 55.8 53.9–57.7 0.0004**
Systolic blood pressure (mmhg) 108 128.5 125.6–131.5 110 124.9 122.2–127.5 0.070
Diastolic blood pressure (mmhg) 108 75.2 73.2–77.1 110 72.5 70.7–74.3 0.051
Mean arterial pressure 108 93.0 90.9–95.1 110 90.0 88.0–91.9 0.038*
Alanine aminotransferase (U/L) 13 40.3 20.7–59.9 25 25.3 21.3–29.4 0.038*
Gamma glutamyl transferase (U/L) 13 52.8 20.2–85.4 25 27.8 18.8–36.8 0.049*
Non-fasting glucose (mmol/L) 103 5.7 5.4–6.0 104 5.2 5.0–5.3 0.004**
Cholesterol (mmol/L) 103 5.6 5.4–5.7 104 5.5 5.3–5.6 0.447
HDL-cholesterol (mmol/L) 103 1.4 1.3–1.4 104 1.5 1.4–1–5 0.074
Triglycerides (mmol/L) 77 1.7 1.5–1.9 90 1.3 1.1–1.4 0.002**
Serum micro C-reactive protein (mg/L) 76 2.2 1.3–3.2 90 1.2 0.9–1.6 0.040*
VO2max: Maximal oxygen uptake, CI: Confidence Interval, BMI: Body Mass Index, HDL: High Density Lipoprotein. P-values below 0.05 are flagged. **p,0.005, *p,0.05.
doi:10.1371/journal.pone.0042330.t001
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heart, high PLD activity and increased level of PA are suggested to
be involved in the signaling cascade promoting pathological
cardiac hypertrophy [13]. If our assumptions are correct, even
healthy individuals with a low aerobic fitness may have a high
PLD activity, which may link low aerobic fitness to the future
development of CVD.
Other explanation for the high levels of serum choline in the low
VO2max-group may be release of choline from damaged organs,
impaired tissue uptake or choline-rich diet [14,15]. In patients
with severe repetitive arrhythmias and hemodynamic compromis-
es, choline has been shown to leak from ischemic tissues into the
blood stream [16–18]. However, since the participants in the
current study were healthy it seems unlikely that the increased
levels of choline arise from myocardial release. Regarding diet, a
previous study indicated a weak inverse association between serum
choline and time since last meal [19]. In the current study the
groups were matched on fasting status, and no important
differences were found in diet. Thus, the observed differences in
free choline levels are not likely to be caused by differences in food
intake.
High serum levels of free choline have previously been
associated with an increased prevalence of the metabolic syndrome
(a cluster of risk factors of CVD) [19]. Since the subjects in the low
VO2max-group not fulfilled the criteria for the metabolic
syndrome, our results may indicate that serum levels of choline
may have prognostic value for future CVD even among healthy
subjects. Free choline levels should therefore be assessed in a large
healthy cohort to prospectively study the prognostic value for later
cardiovascular events. Furthermore, elevated levels of choline have
recently been recognized as a novel biomarker for early risk
stratification in patients with suspected acute coronary syndrome
[16–18]. To our knowledge, no previous study has reported
associations between VO2max level and free choline.
In addition to the differences in choline-containing compounds,
the MR spectra also indicated that the subjects with low VO2max
had decreased amounts of unsaturated fatty acids. Decreased
serum levels of unsaturated fatty acids have previously been
associated with increased risk of CVD [20].
The differences in weight, waist circumference, waist-to-hip-
ratio, BMI, mean arterial blood pressure, resting heart rate, non-
Table 2. Data from questionnaires.
Variable Low VO2max-group High VO2max-group p-value
n mean CI n mean CI
Own reported health status (scale 1–4) 104 3.0 2.8–3.1 107 3.3 3.2–3.4 0.001**
Vegetables intake (scale 1–5) 108 3.5 3.3–3.6 110 3.6 3.4–3.7 0.293
Fruit and berry intake (scale 1–5) 108 3.4 3.2–3.7 110 3.8 3.6–4.0 0.029*
Sausage and hamburger intake (scale 1–5) 108 1.3 1.3–1.5 108 1.2 1.2–1.4 0.102
High-fat fish intake (scale 1–5) 108 1.5 1.5–1.8 108 1.5 1.4–1.7 0.730
Food intake: 1 = 0–3 times a month, 2 = 1–3 times a week, 3 = 4–6 times a week, 4 =Once a day, 5 = 2 times or more each day. VO2max: Maximal oxygen uptake, CI:
Confidence interval. P-values below 0.05 are flagged. **p,0.01, *p,0.05.
doi:10.1371/journal.pone.0042330.t002
Figure 1. Principal Component Analysis (PCA) of the serum 1H MR spectra. (A) In the score plot, high VO2max subjects are shown in green
(higher density in upper left part) and low VO2max subjects are shown in red. (B) The loadings plot visualizes the differences in metabolites between
the two groups. The signals originating from within the core of the serum lipoprotein particles (-CH3 at 0.86 ppm, -CH2- at 1.3 ppm) and choline-
containing compounds (-N (CH3)3
+, at 3.24 ppm) are mainly responsible for the clustering. VO2max: Maximal oxygen uptake.
doi:10.1371/journal.pone.0042330.g001
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Figure 2. Visualization of the metabolic differences in MR spectra. The green spectrum is from a high VO2max subject (green dots in PCA
score plot) and the red spectrum is from the low VO2max (red dots in PCA score plot). VO2max: Maximal oxygen uptake.
doi:10.1371/journal.pone.0042330.g002
Figure 3. Representative 1H NOESYGPPR 1D spectra with assignments of the main metabolites. The spectra in red (and black) consist of
5 spectra (superimposing) from two of the subjects. The reproducibility was evaluated by PCA and the score plot shows the spectra from all 6
subjects, clearly depicting larger inter subject variance compared to intra subject variance. NACl and NAC2 refer to composite acetyl signals from a1-
acid glycoprotein. PCA: Principal Component Analysis.
doi:10.1371/journal.pone.0042330.g003
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fasting glucose, triglycerides, micro-CRP between the high and
low VO2max-groups are supported by previous findings [21–23].
In addition, the increased levels of circulating liver enzymes
(ALAT and Gamma-GT) in the low VO2max-group may reflect
more liver fat and increased insulin resistance [24]. Previous
results from a study of rats with genetically low aerobic capacity
indicate that low VO2max impairs the hepatic oxidative capacity
and therefore contributes to increased amounts of liver fat [25].
Elevated levels of Gamma-GT, even within the normal range,
have previously been associated with the presence of CVD risk
factors, metabolic syndrome, and type 2-diabetes [26,27].
Ideally, obtaining blood samples after overnight fasting would
be preferable due to the elimination of chylomicrones from the
circulation further enabling a more detailed overview of lipids and
lipoprotein sub-classes [28]. However, fasting for several hours is
neither easy to accomplish in a population-based large-scale study,
nor preferable when performing a VO2max-test. In addition to a
possible influence on the lipid metabolites in the MR spectra, it is
also possible that the lack of fasting may have interfered with the
results on glucose and total cholesterol levels. In this study there
was no difference in total cholesterol levels between the high and
low VO2max-group. Previous studies have reported inverse
correlation between VO2max and total cholesterol [29,30].
In conclusion, low VO2max is associated with elevated levels of
free choline and decreased levels of phosphatidylcholine, even in a
cohort of healthy individuals. The precise reason for the shift in
the choline/phosphatidylcholine ratio between subjects in the high
versus the low VO2max-group is unclear, but might be associated
with phospholipase activity, or differences in cardiac or hepatic
release. Further studies should be conducted on free choline and
phosphatidylcholine to validate their potential as early risk-
markers of CVD and predictors of VO2max.
Materials and Methods
Study Participants
The third wave of the Nord-Trøndelag Health Study (HUNT3)
in Norway was carried out between 2006 and 2008 and the results
reported in the present publication stems from this part of the
large HUNT study. Among 50,821 participants in HUNT3, 4631
healthy, adult subjects attended a sub-study designed to measure
VO2max, called the Fitness Study [31]. Participants in the Fitness
Study reported to be free from heart- or lung-disease (details
previously described [31]). From the Fitness Study-population, 220
individuals between 40 and 59 years were selected pair-wise with
one having low and the other high VO2max (selected from top or
bottom 15 subjects within each age-year), but otherwise same
gender, equal age in years, same physical activity index score
(within 15% difference) and equal time since last meal. Subjects
were ranged according to VO2max reported as mL?kg
20.75?min21,
and maximum five pairs of subjects were matched from each age-
year. Two subjects did not provide a blood sample, and the study
thus included 218 subjects (45 males and 63 females in the low
VO2max-group, and 46 males and 64 females in the high VO2max-
group).
The study was approved by the Regional Committee for
Medical Research Ethics, the Norwegian Data Inspectorate, and
by the National Directorate of Health. The study is in conformity
with Norwegian laws and the Helsinki declaration, and all
participants signed a document of consent.
Clinical Measurements
Weight and height were measured on a combined scale (Model
DS-102, Arctic Heating AS, Nøtterøy, Norway), and BMI was
calculated as weight divided by height squared (kg m22). Blood
pressure and resting heart rate were both measured while sitting
(Critikon Dinamap 845XT, GE Medical Systems, Little Chalfont,
Buckinghamshire, United Kingdom) and followed established
guidelines [32].
An individualized protocol was applied to measure VO2max
treadmill running to exhaustion [33]. The VO2max-test was
performed using a ramp protocol where the speed was constant
and the incline was increased with 2% every second minute until
VO2max was reached. Oxygen uptake kinetics were measured
directly by a portable mixing chamber gas-analyzer (Cortex
MetaMax II, Cortex, Leipzig, Germany) with the participants
wearing a tight face mask (Hans Rudolph, Kansas City, USA)
connected to the MetaMax II. The system has previously been
found valid [34]. Heart rate was measured by radio telemetry
(Polar S610i, Polar Electro Oy, Kempele, Finland). From the
warm-up pace, the load was regularly increased when oxygen
uptake kinetics flattened. Along with a respiratory quotient of 1.05
or higher, a maximal test was considered achieved when the
oxygen uptake did not increase more than 2 mL?kg21?min21 at
the highest effort or before the participant disembarked the
treadmill [35]. VO2max was measured as litres of oxygen per
minute (L?min21), and subsequently calculated as VO2max relative
to body mass (mL?kg21?min21) and VO2max scaled
(mL?kg20.75?min21).
Blood Analysis
All clinical-chemical analyses were performed on fresh venous
non-fasting blood samples at Levanger Hospital, Norway. Non-
fasting glucose (mmol/L) was analysed by Hexokinase/G-G-PDH
methodology (reagent kit 3L82-20/3L82-40 Glucose, Abbot,
Clinical Chemistry, USA). HDL-cholesterol (mmol/L) was ana-
lysed by Accelerator selective detergent methodology (reagent kit
3K33-20 Ultra HDL, Abbot, Clinical Chemistry, USA). Triglyc-
erides (mmol/L) were analysed by Glycerol Phosphate Oxidase
methodology (reagent kit; 7D74 Triglyceride, Abbot, Clinical
Chemistry, USA). Creatinine (mg/dl) was analysed by Alkaline
Picrate methodology (reagent kit; 7D65-20 Creatinine, Abbot,
Clinical Chemistry, USA). Alanine aminotransferase (U/L) was
analysed by NADH (with P-59-P) methodology (reagent kit; 8D36-
30 Alanine aminotransferase activated, Abbot, Clinical Chemistry,
USA). Measurements below the instrument range were recorded
as 9 U/L. Gamma glutamyl transferase (Gamma-GT) (U/L) was
analysed by L-Gamma-glytamyl-3-carboxy-4-nitroanilide sub-
strate methodology (reagent kit; 7D65-20 Gamma-glutamyl
transferase, Abbot, Clinical Chemistry, USA). Measurements
below and above instrument range were recorded as 3 U/L and
1544 U/L, respectively. Serum micro C-reactive protein (mg/L)
was analysed by Areoset CRP Vario kit (Abbot, Clinical
Chemistry, USA). Measurements below instrument range are
recorded as 0.
Questionnaire-based Information
Physical activity was registered based on the responses to a self-
administered questionnaire applied (http://www.ntnu.edu/hunt/
data/que) [36]. The questionnaires included three questions:
Question 1: ‘‘How frequently do you exercise?’’, with the response
options ‘‘Never’’ (0), ‘‘Less than once a week’’ (0), ‘‘Once a week’’
(1), ‘‘2–3 times per week’’ (2.5) and ‘‘Almost every day’’ (5).
Question 2: ‘‘If you exercise as frequently as once or more times a
week: How hard do you push yourself?’’ with the response options:
‘‘I take it easy without breaking a sweat or losing my breath’’ (1), ‘‘I
push myself so hard that I lose my breath and break into sweat’’ (2)
and ‘‘I push myself to near exhaustion’’ (3). Question 3: ‘‘How
Metabolites and Fitness in Healthy Subjects
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long does each session last?’’, with the response options: ‘‘Less than
15 minutes’’ (0.1), ‘‘16–30 minutes’’ (0.38), ‘‘30 minutes to
1 hour’’ (0.75) and ‘‘More than 1 hour’’ (1.0). Each participant’s
response to the above mentioned three questions (i.e. numbers in
brackets) were multiplied to calculate a physical activity index
score [36]. As the second and third question only addressed people
who exercised at least once a week, both ‘‘Never’’ and ‘‘Less than
once a week’’ yielded an index score of zero. Participants with a
zero score were categorized as inactive.
Dietary habits were self-reported in a questionnaire. For ‘‘Fruit
and berries’’, ‘‘Vegetables’’, ‘‘Sausages/hamburgers’’ and ‘‘High-
fat fish’’ the possible response-options were ‘‘0–3 times a month’’
(1), ‘‘1–3 times a week’’ (2), ‘‘4–6 times a week’’ (3), ‘‘once a day’’
(4), and ‘‘twice or more a day’’ (5). Health-status was also self-
reported and the options were ‘‘bad’’ (1), ‘‘not quite good’’ (2),
‘‘good’’ (3), or ‘‘very good’’ (4). The mean values were calculated
from the answers from all the participants in each group (i.e.
numbers in brackets).
Metabolic Profiling
Venous non-fasting blood samples were collected in serum-
tubes with no additives. The blood was centrifuged at 3000 rpm
for 10 minutes approximately 1 hour after sample collection. The
serum samples were stored at 280uC in the biobank until being
used for metabolic profiling. The serum samples were slowly
thawed at 4uC. Aliquots of 150 mL were mixed with equal
amounts of buffer solution (Na2HPO4 67H2O (0.075M), 4%
NaN3 in H2O (5ml, mass % of NaN3 versus mass % of H2O), TSP
(3-(trimethyl-silyl) propionic acid-d4, 0.4g), D2O (100 mL), pH
adjusted to 7.4 with 1M HCl (1M NaOH), filled up to 500 mL
with H2O) and transferred to high-quality 3 mm MR tubes. The
ratio between H2O and D2O was 90:10 in all samples. In order to
assess the reproducibility of sample preparation and spectral
acquisition, our daily protocol included a set of five samples
individually prepared from a single healthy individual every day.
MR Experiments
The MR spectra were acquired using a Bruker Avance II
(Bruker Biospin, Rheinstetten, Germany) with digital receiver unit
(DRU) operating at 600 MHz for proton (1H). The probe was a
TCI 1H-13C/15N/D with z-gradient and automated tuning and
matching unit. All spectra were recorded in an automatic fashion
using a BACS-60 sample changer and the ICON-NMR software
(Bruker Biospin). Proton spectra were obtained at a constant
temperature of 310 K using a modified Carr-Purcell-Meiboom-
Gill (CPMG) pulse sequence with presaturation during the
relaxation delay (Bruker: cpmgpr1d) to achieve water suppression
and to facilitate the detection of low molecular weight species by
avoiding the large overlapped signals derived from proteins and
large molecules. The spectra were collected with 64 scans and 4
dummy scans. The acquisition time is set to 3.067 sec, measuring
the FID via collection of 36864 complex data point resulting in a
sweep width of 20.0363 ppm. A relaxation delay of 4 seconds was
used, during which a presaturation of 25 Hz was applied. Effective
echo time was 80ms and data acquisition starts at maximum of last
echo. An exponential apodization of 1Hz was applied prior to
Fourier transform. Measurement and processing was done in full
automation using Bruker standard automation programs con-
trolled by ICON-NMR (along with TopSpin v2.1 patchlevel 6).
Chemical shift was calibrated to the middle of the alanine peaks at
1.50 ppm. The reproducibility spectra were acquired using
nuclear Overhauser effect spectroscopy (NOESY, Bruker: noe-
sygppr1d) with the same parameters as CPMG with the exception
of 32 scans. The assignments of chemical shifts were done on the
basis of previously published data [37].
Data Processing and Multivariate Analysis
Data analysis was performed with MATLAB (Version 7.9.0;
The Math Works, Natick, MA, USA). The spectra were divided
into 850 segments, each 0.01 ppm wide for a spectral window
ranging from 0.5 to 9.0 ppm to reduce minor chemical shift
alterations [38]. The segments between 4.5–5.0 ppm were
excluded to remove variation in water suppression efficiency.
Spectra were finally normalized by setting the total spectral area to
a constant value ( = 1) for all spectra to minimize possible
differences in serum concentration between the samples.
Unsupervised principal component analysis (PCA) and super-
vised partial least squares discriminant analysis (PLS-DA) were
performed using PLS_Toolbox v5.8.3 (Eigenvector Research,
Manson, WA, USA). PCA reduces the dimensionality of the data
and summarizes the structure of the multiple MR spectra
visualized in score plots and loading profiles. The variance
structure of the data is explained through linear combinations of
the variables called principal components (PCs). The first PCs will
be in the direction explaining most of the variance in the data set.
In the score plot of the PCs, samples with a similar metabolic
profile will cluster, while the corresponding loading profile displays
the importance of each variable within the PC. PLS-DA is a
supervised classification method which uses the class information
to detect variables generating maximum separation between the
classes (high and low aerobic capacity). All statistical models were
cross-validated with a single 10-fold Venetian blind cross
validation; in each run 10% of the data were left out of the
training and used to test the model. The optimal model contains
the number of latent variables yielding the lowest percentage of
misclassification. A permutation test was performed (10000
permutations) to evaluate the significance of the difference
between the classes [39].
To evaluate the reproducibility of the sample preparation and
metabolomics analyses, PCA of the replicate spectra from single
subjects (in total 30 sample preparations from 6 subjects) were
performed for comparison of the inter versus intra subject
variance.
Colorimetric Analysis of Free Choline
In a sub-cohort of 39 participants (20 women and 19 men) from
the low VO2max-group and 38 participants (21 women and 17
men) from the high VO2max-group, the level of free choline was
measured in serum. The groups were matched on fasting status,
age and physical activity index score. The serum was analysed
with the Choline/Acetylcholine Quantification Kit according to
the manufacturer’s instructions (Abnova, Taipei City, Taiwan).
Statistical Analyses
PASW Statistics 17.0 (IBM, New York, USA) was used for
traditional statistical analyses. All statistical tests were two-sided,
and p-values below 0.05 were considered statistical significant.
Kolmogorov-Smirnov test was used to test for normality. One-
Way ANOVA was used for comparing variables between the high
and the low VO2max-groups, and Kruskal-Wallis test was used in
non-parametric analyses. Results are given in mean 6 SE.
Pearson’s correlation was used to study associations between
normally distributed variables, and Spearman’s correlation was
used in non-parametric analyses. The correlation analyses were
performed separately for the high and low VO2max-group.
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